[go: up one dir, main page]

WO2009114321A2 - Rationally-designed meganucleases for maize genome engineering - Google Patents

Rationally-designed meganucleases for maize genome engineering Download PDF

Info

Publication number
WO2009114321A2
WO2009114321A2 PCT/US2009/035719 US2009035719W WO2009114321A2 WO 2009114321 A2 WO2009114321 A2 WO 2009114321A2 US 2009035719 W US2009035719 W US 2009035719W WO 2009114321 A2 WO2009114321 A2 WO 2009114321A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
seq
lig
meganuclease
dna
Prior art date
Application number
PCT/US2009/035719
Other languages
French (fr)
Other versions
WO2009114321A8 (en
WO2009114321A3 (en
Inventor
Derek Jantz
James Jefferson Smith
Original Assignee
Precision Biosciencs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biosciencs, Inc. filed Critical Precision Biosciencs, Inc.
Publication of WO2009114321A2 publication Critical patent/WO2009114321A2/en
Publication of WO2009114321A8 publication Critical patent/WO2009114321A8/en
Publication of WO2009114321A3 publication Critical patent/WO2009114321A3/en
Priority to US12/879,428 priority Critical patent/US8338157B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses

Definitions

  • the invention relates to the field of molecular biology and recombinant nucleic acid technology.
  • the invention relates to a rationally-designed, non- naturally-occurring meganuclease with altered DNA recognition sequence specificity which recognizes and cleaves a unique DNA site in the maize genome.
  • the invention also relates to methods of producing engineered maize plants using such meganucleases.
  • Genome engineering requires the ability to insert, delete, substitute and otherwise manipulate specific genetic sequences within a genome, and has numerous therapeutic and biotechno logical applications.
  • the development of effective means for genome modification remains a major goal in gene therapy, agrotechnology, and synthetic biology (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73; Tzfira et al. (2005), Trends Biotechnol. 23: 567-9; McDaniel et al. (2005), Curr. Opin. Biotechnol. 16: 476-83).
  • a common method for inserting or modifying a DNA sequence involves introducing a transgenic DNA sequence flanked by sequences homologous to the genomic target and selecting or screening for a successful homologous recombination event. Recombination with the transgenic DNA occurs rarely but can be stimulated by a double-stranded break in the genomic DNA at the target site. Numerous methods have been employed to create DNA double-stranded breaks, including irradiation and chemical treatments. Although these methods efficiently stimulate recombination, the double-stranded breaks are randomly dispersed in the genome, which can be highly mutagenic and toxic. At present, the inability to target gene modifications to unique sites within a chromosomal background is a major impediment to successful genome engineering.
  • One approach to achieving this goal is stimulating homologous recombination at a double-stranded break in a target locus using a nuclease with specificity for a sequence that is sufficiently large to be present at only a single site within the genome (see, e.g. , Porteus et al. (2005), Nat. Biotechnol. 23: 967-73).
  • the effectiveness of this strategy has been demonstrated in a variety of organisms using chimeric fusions between an engineered zinc finger DNA-binding domain and the non-specific nuclease domain of the Fokl restriction enzyme (Porteus (2006), MoI Ther 13: 438-46; Wright et al. (2005), Plant J.
  • a group of naturally-occurring nucleases which recognize 15-40 base-pair cleavage sites commonly found in the genomes of plants and fungi may provide a less toxic genome engineering alternative.
  • Such naturally-occurring “meganucleases” or “homing endonucleases” are frequently associated with parasitic DNA elements, such as group I self- splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), Q. Rev. Biophys. 38: 49-95).
  • LAGLIDADG Meganucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The LAGLIDADG meganucleases with a single copy of the LAGLIDADG motif form homodimers, whereas members with two copies of the LAGLIDADG motif are found as monomers.
  • the GIY-YIG family members have a GIY-YIG module, which is 70-100 residues long and includes four or five conserved sequence motifs with four invariant residues, two of which are required for activity (see Van Roey et al. (2002), Nature Struct. Biol. 9: 806-811).
  • the His-Cys box meganucleases are characterized by a highly conserved series of histidines and cysteines over a region encompassing several hundred amino acid residues (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774).
  • the members are defined by motifs containing two pairs of conserved histidines surrounded by asparagine residues (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774).
  • the four families of meganucleases are widely separated from one another with respect to conserved structural elements and, consequently, DNA recognition sequence specificity and catalytic activity.
  • LAGLIDADG which recognizes and cuts a 22 base-pair recognition sequence in the chloroplast chromosome, and which presents an attractive target for meganuclease redesign.
  • the wild-type enzyme is a homodimer in which each monomer makes direct contacts with 9 base pairs in the full-length recognition sequence.
  • Genetic selection techniques have been used to identify mutations in I-Crel that alter base preference at a single position in this recognition sequence (Sussman et al. (2004), J. MoI. Biol. 342: 31-41; Chames et al. (2005), Nucleic Acids Res. 33: el78; Seligman et al. (2002), Nucleic Acids Res.
  • the I-Crel protein-DNA interface contains nine amino acids that contact the DNA bases directly and at least an additional five positions that can form potential contacts in mutant interfaces. The size of this interface imposes a combinatorial complexity that is unlikely to be sampled adequately in sequence libraries constructed to select for enzymes with drastically altered cleavage sites.
  • nucleases that will facilitate precise modification of a genome by cleaving any desired genomic sequence, including sequences not cleaved by naturally-occurring homing endonucleases. This is particularly true of the agriculture industry in which the production of genetically modified crop lines is significantly hindered by the current inability to target the insertion or removal of nucleic acids from specific regions of the genome.
  • the present invention provides, inter alia, an engineered meganucleases which recognize a unique DNA sequence found in the Zea mays (maize) genome and methods for using these engineered meganucleases to precisely target the insertion of nucleic acids into the maize genome.
  • the present invention relates to certain engineered meganucleases ("LIG-34 meganucleases”) which recognize and cut a 22 basepair DNA sequence found in the genome of Zea mays (maize).
  • LIG-34 meganucleases engineered meganucleases
  • the invention provides a composition comprising a LIG34 meganuclease, a maize plant comprising an exogenous DNA sequence in its chromosome, as well as methods that use LIG34 meganucleases to target the insertion of nucleic acids into a specific locus in the maize genome.
  • the invention provides a rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 1. In another aspect, the invention provides a rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 12. In yet another aspect, the invention provides a rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 13.
  • the invention provides a rationally-designed meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3.
  • the invention provides a method for the production of a recombinant maize plant in which a sequence of interest is integrated the maize genome, the method comprising transforming a maize cell or embryo with: (a) a first DNA molecule comprising: a DNA sequence encoding a meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3; and a promoter suitable for the expression of such a meganuclease in maize; and (b) a second DNA molecule comprising a sequence of interest.
  • the invention provides a method for the production of a recombinant maize plant in which a sequence of interest is integrated the maize genome, the method comprising transforming a maize cell or embryo with: (a) a first DNA molecule comprising: a DNA sequence encoding a meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3; and a promoter suitable for the expression of such a meganuclease in maize; and (b) a second DNA molecule comprising: a sequence of interest flanked on one side by a DNA sequence with homology to 50-900 consecutive base pairs of SEQ ID NO: 10 and flanked on the other side by a DNA sequence with homology to 50-900 consecutive base pairs of SEQ ID NO: 11.
  • the sequence of interest can be flanked on at least one side by the first nine nucleotides from the meganuclease recognition sequence of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the maize cell or embryo can be transformed with a molecule comprising the first DNA molecule and the second DNA molecule.
  • the maize cell or embryo can be transformed with a molecule comprising the first DNA molecule and the second DNA molecule and wherein SEQ ID NO: 2 or SEQ ID NO: 3 is located between the DNA sequence encoding the meganuclease and the sequence of interest.
  • the invention provides a maize plant with a chromosome comprising a composite sequence, the composite sequence comprising: a sequence of interest; a first sequence comprising 50-900 base pairs from SEQ ID NO: 10 immediately upstream of the sequence of interest; and a second sequence comprising 50-900 base pairs from SEQ ID NO: 11 immediately downstream of the sequence of interest.
  • the sequence of interest can comprise an exogenous gene.
  • the composite sequence is free of retroviral sequences, Agrobacterium tumefaciens sequences and/or transposon sequences.
  • the maize plant has a single composite sequence in said chromosome.
  • the 3' nucleotide of the first sequence corresponds to a nucleotide selected from the group consisting of nucleotides 950- 961 of SEQ ID NO: 10.
  • the 5' nucleotide of the second sequence corresponds to a nucleotide selected from the group consisting of nucleotides 1-11 of SEQ ID NO: 11.
  • the invention provides a maize plant having a sequence of interest inserted in its chromosome, wherein the sequence of interest is inserted into SEQ ID NO: 2 and SEQ ID NO: 3. [0019] In some embodiments, the sequence of interest is inserted only once into said chromosome.
  • the sequence of can interest can comprise an exogenous gene.
  • FIG. 1 illustrates the interactions between the LIG-34 meganuclease and its double-stranded recognition sequence found in the maize genome.
  • This schematic representation depicts the recognition sequence (SEQ ID NO: 2 and SEQ ID NO: 3), shown as unwound for illustration purposes only, bound by the LIG-34 meganuclease.
  • the N- and C-terminal domains of LIG-34 are shown as two ovals.
  • the bases of each DNA half-site are numbered -1 through -9, and the amino acid residues of LIG-34 which form the recognition surface are indicated by one-letter amino acid designations and numbers indicating residue position. Amino acids with asterisks are mutant relative to wild-type I-Crel.
  • Solid black lines hydrogen bonds and hydrophobic contacts to DNA bases. Arrows: residues that interact with the DNA backbone and influence cleavage activity.
  • FIG. 2 is a schematic of a direct-repeat recombination assay used to evaluate the LIG-34 meganucleases.
  • a defective GFP reporter gene was stably integrated into the chromosomal DNA of a human (HEK-293) cell-line.
  • the gene is interrupted by a LIG-34 recognition site which is flanked by -250 base pairs of directly repeated sequence of the GFP gene.
  • FIG. 3 is a bar graph representation of the results of the assay described in
  • the present invention provides engineered meganucleases which specifically recognize and cleave a 22 bp, double-stranded DNA sequence found in the maize genome, that has the sequence shown in SEQ ID NO: 2 and SEQ ID NO: 3, and which is referred to herein as the "LIG-34 recognition site.” These meganucleases are produced, in part, in accordance with the methods disclosed in WO 2007/047859. Examples of such meganucleases include those designated herein as "LIG-34" (SEQ ID NO: 1), “LIG-34+” (SEQ ID NO: 12) and “LIG-34++” (SEQ ID NO: 13).
  • WO 2007/047859 which is incorporated herein by reference, describes a method for the production of meganucleases derived from the natural I-Crel homing endonuclease, but that recognize DNA sequences that differ from the sequence recognized by wild-type I-Crel.
  • LIG34 meganucleases The LIG-34, LIG-34+, LIG-34++ meganucleases, as well as other meganucleases produced according to the methods disclosed in WO 2007/047859, and that recognize and cleave the LIG-34 recognition site, are collectively referred to herein as "LIG34 meganucleases.”
  • LIG34 meganucleases can be used for cleaving a unique DNA site in the genome of Zea mays and thereby enable gene insertion at that site in the genome.
  • This invention will have a significant impact on the agriculture industry as it allows seed producers to generate transgenic maize plants in which trait genes of agronomic value (e.g., herbicide resistance genes, insect resistance genes, drought tolerance genes, disease resistance genes, and genes affecting yield or fertility) are inserted precisely at the LIG-34 recognition site.
  • trait genes of agronomic value e.g., herbicide resistance genes, insect resistance genes, drought tolerance genes, disease resistance genes, and genes affecting yield or fertility
  • this invention provides a LIG-34 meganuclease. In another embodiment, it provides methods for using a LIG-34 meganuclease to insert transgenes into the maize genome at the LIG-34 recognition site.
  • Naturally-occurring meganucleases can be monomeric (e.g., I-Scel) or dimeric (e.g., I-Crel).
  • the term meganuclease, as used herein, can be used to refer to monomeric meganucleases, dimeric meganucleases, or to the monomers which associate to form a dimeric meganuclease.
  • the term "rationally-designed” means non-naturally occurring and/or genetically engineered.
  • the rationally-designed meganucleases of the invention differ from wild-type or naturally-occurring meganucleases in their amino acid sequence or primary structure, and may also differ in their secondary, tertiary or quaternary structure.
  • the rationally-designed meganucleases of the invention also differ from wild-type or naturally-occurring meganucleases in recognition sequence-specificity and/or activity.
  • the term "recombinant" means having an altered amino acid composition as a result of the application of genetic engineering techniques to nucleic acids which encode the protein, and cells or organisms which express the protein. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion.
  • a protein having an amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous different host is not considered recombinant.
  • the term “genetically-modified” refers to a cell or organism in which, or in an ancestor of which, a genomic DNA sequence has been deliberately modified by recombinant technology. As used herein, the term “genetically-modified” encompasses the term "transgenic.”
  • wild-type refers to any naturally-occurring form of a meganuclease.
  • wild-type is not intended to mean the most common allelic variant of the enzyme in nature but, rather, any allelic variant found in nature. Wild-type meganucleases are distinguished from recombinant or non-naturally-occurring meganucleases.
  • the term "recognition sequence half-site” or simply “half site” means a nucleic acid sequence in a double-stranded DNA molecule which is recognized by a monomer of a mono-LAGLID ADG meganuclease or by one LAGLIDADG subunit of a di- LAGLIDADG meganuclease.
  • the term "recognition sequence” refers to a pair of inverted half-sites separated by four base pairs, which is bound and cleaved by either a mono- LAGLID ADG meganuclease dimer or a di-LAGLIDADG meganuclease monomer.
  • the recognition sequence half-site of each monomer spans 9 base pairs, and the two half-sites are separated by four base pairs, designated Ni through N 4 , which are not recognized specifically.
  • the combined recognition sequence of the I-Crel meganuclease dimer normally spans 22 base pairs, including the 9 base pairs 5' of the central N 1 -N 4 bases on the sense strand, which are designated -9 through -1, the central Ni-N 4 base pairs, and the 9 base pairs 3' of the central Ni-N 4 bases on the sense strand, which are designated -1 through -9.
  • the term “specificity” means the ability of a meganuclease to recognize and cleave double-stranded DNA molecules only at a particular sequence of base pairs referred to as the recognition sequence, or only at a particular set of recognition sequences.
  • the set of recognition sequences will share certain conserved positions or sequence motifs, but may be degenerate at one or more positions.
  • a highly-specific meganuclease is capable of cleaving only one or a very few recognition sequences.
  • the term “palindromic” refers to a recognition sequence consisting of inverted repeats of identical half-sites.
  • the palindromic sequence need not be palindromic with respect to the four central nucleotide pairs, which are not contacted by the enzyme.
  • palindromic DNA sequences are recognized by homodimers in which the two monomers make contacts with identical half-sites.
  • the term "pseudo-palindromic" refers to a recognition sequence consisting of inverted repeats of non-identical or imperfectly palindromic half- sites.
  • the pseudo-palindromic sequence not only need not be palindromic with respect to the four central nucleotide pairs, but also can deviate from a palindromic sequence between the two half- sites.
  • Pseudo-palindromic DNA sequences are typical of the natural DNA sites recognized by wild-type homodimeric meganucleases in which two identical enzyme monomers make contacts with different half- sites.
  • non-palindromic refers to a recognition sequence composed of two unrelated half-sites of a meganuc lease.
  • the non-palindromic sequence need not be palindromic with respect to either the four central nucleotide pairs or the two monomer half- sites.
  • Non-palindromic DNA sequences are recognized by either highly degenerate meganucleases (e.g., I-Ceul) or by heterodimers of meganuclease monomers that recognize non-identical half- sites.
  • the term "activity" refers to the rate at which a meganuclease of the invention cleaves a particular recognition sequence. Such activity is a measurable enzymatic reaction, involving the hydrolysis of phosphodiester bonds of double-stranded DNA.
  • the activity of a meganuclease acting on a particular DNA substrate is affected by the affinity or avidity of the meganuclease for that particular DNA substrate which is, in turn, affected by both sequence-specific and non-sequence-specific interactions with the DNA.
  • LIG-34 recognition site refers to a region of the maize genome approximately 1200 basepairs 5' of the LIGULESSl gene (genbank accession # AF451895) which contains the 22 bp DNA sequence recognized by the LIG-34 meganuclease (SEQ ID NO: 2 and SEQ ID NO: 3).
  • the LIG-34 meganuclease is a derivative of I-Crel that is genetically engineered with respect to its DNA cleavage specificity in accordance with the method disclosed in WO/2007/047859.
  • the amino acid substitutions that were introduced into the LIG-34 meganuclease for the purpose of altering DNA cleavage specificity are diagrammed in Figure 1 and listed in Table 1. Because LIG-34 is a single-chain heterodimeric meganuclease whereas I-Crel is a homodimer and because the LIG-34 meganuclease has an N-terminal nuclease localization signal (as discussed below) the amino acid numbering differs from wild-type I-Crel.
  • Table 1 therefore, also lists the corresponding DNA contacting residue in the amino acid sequence of wild-type I-Crel (SEQ ID NO: 4). [0041] Table 1. Mutations in LIG-34 which alter DNA-cleavage specificity relative to wild-type I-Crel.
  • LIG-34 endonucleases may incorporate additional amino acid substitutions intended to increase the overall cleavage activity of the meganuclease (Table 2).
  • the activity of the LIG-34 meganuclease is increased by reverting negatively-charged amino acids, which were introduced to alter cleavage specificity (E87 and E239, see Table 1) back to the wild-type amino acid.
  • the net effect is a reduction in the overall specificity of the endonuclease, but an increase in endonuclease activity due to the removal of negative charges (which repulse the negatively charged DNA and, thereby, reduce DNA-binding affinity) from the protein-DNA interface.
  • negative charges which repulse the negatively charged DNA and, thereby, reduce DNA-binding affinity
  • the incorporation of glutamine at these amino acid positions whereas wild-type I-Crel has glutamic acid in the corresponding position, eliminates electrostatic repulsion between the negatively-charged glutamic acid sidechain and the negatively-charged DNA.
  • the effect of this pair of substitutions is that the overall DNA binding affinity of the engineered meganuclease is increased with a corresponding increase in the cleavage activity.
  • the introduction of some or all of the modifications listed in Table 2 is useful to restore the level of cleavage activity that is lost upon introducing the mutations listed in Table 1 so that the LIG-34 meganuclease maintains the ability to cleave DNA at a rate that is comparable to wild-type I-Crel.
  • the invention provides a family of engineered meganucleases which cleave the LIG-34 recognition sequence (SEQ ID NO: 2 and SEQ ID NO: 3), but do so with varying degrees of endonuclease activity and/or specificity due to different combinations of the mutations listed in Table 2.
  • LIG-34 is SEQ ID NO: 1, which incorporates the mutations listed in Table 1 as well as Q90 and Q277 from Table 2.
  • a second preferred embodiment is SEQ ID NO: 12, referred to as "LIG-34+", which incorporates the mutations listed in Table 1 as well as Q90, Q277, and T239 (which is a reversion back to a wild-type amino acid).
  • LIG-34+ cleaves the LIG-34 recognition sequence more efficiently in vitro as well as inplanta relative to SEQ ID NO: 1, but has slightly reduced specificity relative to SEQ ID NO: 1.
  • a third preferred embodiment is SEQ ID NO: 13, referred to as "LIG-34++" which incorporates the mutations listed in Table 1 as well as Q90, Q277, C89, 187, and T239 (the latter two are reversions back to a wild-type amino acid).
  • LIG-34++ cleaves the LIG-34 recognition sequence more efficiently in vitro and inplanta than SEQ ID NO:1 and SEQ ID NO: 12, but has reduced specificity relative to SEQ ID NO:1 and SEQ ID NO: 12.
  • the two engineered meganuclease monomers are physically linked to one another using an amino acid linker to produce a single-chain heterodimer.
  • This linker comprises amino acids 166-204 (SEQ ID NO: 7) of LIG-34.
  • the linker sequence joins an N-terminal meganuclease subunit terminated at L 165 (corresponding to L 155 of wild-type I-Crel) with a C-terminal meganuclease subunit starting at K204 (corresponding to K7 of wild-type I-Crel).
  • the benefits of physically linking the two meganuclease monomers using this novel linker are twofold: first, it ensures that the meganuclease monomers can only associate with one another (heterodimerize) to cut the non-palindromic LIG-34 recognition sequence rather than also forming homodimers which can recognize palindromic or pseudopalindromic DNA sites that differ from the LIG-34 recognition sequence. Second, the physical linking of meganuclease monomers obviates the need to express two monomers simultaneously in the same cell to obtain the desired heterodimer. This significantly simplifies vector construction in that it only requires a single gene expression cassette.
  • the LIG-34 meganuclease incorporates an N-terminal nuclear localization signal (NLS, SEQ ID NO: 7) derived from the mammalian SV40 virus. This peptide leader sequence was added to direct the LIG-34 meganuclease to the nucleus of a maize cell. The use of the SV40 NLS sequence is common in the art. [0047] The LIG-34 meganucleases of SEQ ID NO: 1, SEQ ID NO: 12, and SEQ ID NO: 7)
  • the LIG-34 meganuclease is used to cause a double-stranded break at the LIG-34 recognition site to allow for precise insertion(s) of a sequence of interest into that site by homologous recombination.
  • the LIG-34 meganuclease is used to cause a double- stranded break at the LIG-34 recognition site to allow for precise insertion(s) of a sequence of interest into that site by non-homologous end-joining.
  • sequence of interest means any DNA sequence that can be inserted into the maize genome. Sequences of interest will typically be genes that confer commercially valuable traits to maize plants (e.g., genes that confer herbicide resistance, genes that confer insect resistance, genes that confer disease resistance, genes that confer drought resistance, genes that improve nutritional value, genes that improve yield or quality, and genes that affect plant fertility) as well as transcription regulation sequences (e.g., a promoter and transcription terminator) to control expression of the trait gene.
  • genes that confer herbicide resistance genes that confer insect resistance, genes that confer disease resistance, genes that confer drought resistance, genes that improve nutritional value, genes that improve yield or quality, and genes that affect plant fertility
  • transcription regulation sequences e.g., a promoter and transcription terminator
  • regulatory sequences include, but are not limited to, constitutive plant promoters such as the NOS promoter, The 35S promoter, or the UBI promoter, chemically-inducible gene promoters such as the dexamethasone-inducible promoter (see, e.g., Gremillon et ⁇ l. (2004), Plant J. 37:218-228), and plant tissue specific promoters such as the LGCl promoter (see, e.g., Singh et al. (2003), FEBS Lett. 542:47-52).
  • the term "homologous recombination” refers to a natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, e.g., Cahill et al. (2006),Front. Biosci. 11 :1958-1976).
  • the LIG-34 meganuclease is used to cleave the LIG-34 recognition site in a maize cell and a sequence of interest flanked by DNA sequence with homology to the LIG-34 recognition site is delivered into a maize cell and used as a template for repair by homologous recombination. The sequence of interest is thereby incorporated into LIG-34 recognition site.
  • non-homologous end-joining refers to a natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, e.g., Cahill et al. (2006), Front. Biosci. 11 :1958- 1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the capture of exogenous DNA sequences at the site of repair joining (see, e.g., Salomon, et al. (1998), EMBOJ. 17:6086-6095). This is particularly true of exogenous DNA sequences delivered by Agrobacterium tumefaciens.
  • the LIG-34 meganuclease can be used to produce a double-stranded break at the LIG-34 recognition site in a maize cell and a sequence of interest, which may or may not have homology to the LIG- 34 recognition site, can be delivered to a maize cell and be captured at the LIG-34 site by non-homologous end-joining.
  • the sequence of interest is, thereby, incorporated into the LIG-34 recognition site.
  • nucleic acids to maize cells are well known in the art and include Agrobacterium infection, PEG-mediated transformation of protoplasts (Omirulleh et al. (1993), Plant Molecular Biology, 21 :415-428), desiccation/inhibition-mediated DNA uptake, electroporation, agitation with silicon carbide fibers, ballistic injection or microprojectile bombardment, biolistic injection (Lorence and Verpoorte (2004), Methods MoI. Biol., 267: 329-50) and the like. Also, as a general rule, the method of gene delivery can be correlated with the activity level of the LIG-34 meganuclease.
  • Meganucleases with lower activity are advantageously delivered by Agrobacterium infection or a related method which efficiently produces stable transformants (i.e. produces plants in which the LIG-34 gene is integrated stably into the plant genome). This is because long-term exposure to meganuclease is more likely to yield high-efficiency DNA cleavage by such reduced-activity meganucleases.
  • microprojectile bombardment of plasmid DNA, biolistic injection, or similar methods which can result in transient gene delivery (i.e.
  • the meganuclease gene is NOT integrated into the genome and is NOT selected for and, thus, is lost over time) are advantageous for delivering very high activity LIG-34 meganucleases (such as SEQ ID NO: 13) because long-term exposure to a high-activity LIG-34 meganuclease is not necessary for high-efficiency cleavage of the LIG-34 recognition sequence and may lead to toxicity due to off-target DNA cleavage.
  • LIG-34 meganucleases such as SEQ ID NO: 13
  • the methods of the invention involve the delivery of a sequence of interest as well as the gene encoding the LIG-34 meganuclease into a single maize cell or embryo which can be grown into a mature recombinant maize plant and give rise to progeny carrying the inserted sequence of interest in its genome.
  • aspects of the invention allow for the use of the LIG-34 meganuc lease to introduce a sequence of interest into the LIG-34 recognition site by homologous recombination. Such methods require two components:
  • the LIG-34 expression cassette is a DNA molecule encoding the LIG-34 meganuclease under the control of a promoter suitable for the expression of the meganuclease gene in a maize cell.
  • promoters are known in the art and include, preferably, constitutive plant promoters such as the nopaline synthase (nos) promoter, the CaMV 35 S promoter, or the plant ubiquitin (Ubi) promoter.
  • constitutive plant promoters such as the nopaline synthase (nos) promoter, the CaMV 35 S promoter, or the plant ubiquitin (Ubi) promoter.
  • chemically-inducible gene promoters such as the dexamethasone- inducible promoter (see, e.g., Gremillon et al. (2004), Plant J.
  • LIG-34 meganuclease may be used.
  • the choice of promoter may be correlated with the activity level of the LIG-34 meganuclease and/or choice of gene delivery method.
  • strong, constitutive promoters such as Ubi or CaMV 35S are preferred for low- activity LIG-34 meganucleases (such as SEQ ID NO: 1) and for applications in which the meganuclease gene is delivered transiently (such as microprojectile bombardment in the absence of selection for stable transformants).
  • inducible promoters such as SEQ ID NO: 13
  • tissue-specific promoters such as SEQ ID NO: 13
  • weak constitutive promoters are preferred for high-activity meganucleases (such as SEQ ID NO: 13) in cases where the meganuclease expression cassette is stably integrated into the plant genome for long-term expression of the meganuclease gene.
  • the LIG-34 meganuclease coding sequence will be optimized for expression in eukaryotic cells ⁇ e.g., SEQ ID NO: 9).
  • the LIG- 34 gene will be followed by a transcription terminator sequence such as the nopaline synthase (nos) terminator.
  • the homologous donor cassette This component is a DNA molecule harboring a sequence of interest flanked on one or, preferably, both sides by regions of homology to the LIG-34 recognition site.
  • the region(s) of homology will be at least 50 base pairs in length and can be, 50-900, 50-1000, 500-900, or 500-1000 base pairs in length.
  • the sequence of interest will be flanked on one side by 50-900, 50- 1000, 500-900, or 500-1000 bases that are identical or nearly identical to the DNA sequence immediately 5' of the LIG-34 recognition sequence (including the 5' LIG-34 recognition half-site) and will be flanked on the other side by 50-900, 50-1000, 500-900, or 500-1000 bases that are identical or nearly identical to the DNA sequence immediately 3' of the LIG-34 recognition sequence (including the 3' LIG-34 recognition half-site).
  • an effective donor cassette may have the following composition: 5'-[50-9OO consecutive base pairs SEQ ID NO: 10] - [sequence of interest] - [50-900 consecutive base pairs SEQ ID NO: 11] - 3'.
  • an effective donor cassette may have the following composition: 5'-[50-10OO consecutive base pairs SEQ ID NO: 10] - [sequence of interest] - [50-1000 consecutive base pairs SEQ ID NO: 11] - 3'.
  • the homologous donor cassette may or may not be harbored on the same DNA molecule as the LIG-34 expression cassette.
  • the LIG-34 expression cassette and the homologous donor cassette are delivered simultaneously to individual maize cells or maize embryos.
  • the LIG-34 expression cassette is delivered first to individual maize cells or maize embryos and the homologous donor cassette is delivered subsequently to the same cell or embryo.
  • Transformed cells are then grown into calli or plants and are screened (e.g., by PCR) for individuals in which the sequence of interest integrated into the LIG-34 recognition site by homologous recombination or non-homologous end-joining.
  • the sequence of interest is a selectable marker gene (e.g., an herbicide resistance gene) and transformed plants can be selected for under the appropriate growth conditions (e.g., in the presence of herbicide) followed by molecular screening to identify individuals in which the sequence of interest integrated at the LIG-34 recognition site.
  • a selectable marker gene e.g., an herbicide resistance gene
  • aspects of the invention allow for the use of the LIG-34 meganuc lease to introduce a sequence of interest into the LIG-34 recognition site by Non-Homologous End- Joining.
  • Such methods require two components: [0059] 1.
  • the non-homologous donor cassette This component comprises, at a minimum, the sequence of interest with no additional DNA sequence.
  • the non-homologous donor cassette may comprise the sequence of interest flanked on one or both sides by the LIG-34 recognition sequence. In the latter case, cleavage of the nonhomologous donor cassette by the LIG-34 meganuclease will result in four basepair 3' "sticky ends" on one or both sides of the sequence of interest that are compatible with the sticky ends produced by cleavage of the LIG-34 recognition site which may facilitate integration of the sequence of interest by non-homologous end-joining.
  • the non-homologous donor cassette may be housed on the same DNA molecule as the LIG-34 expression cassette only if the two are separated by a LIG-34 recognition sequence which can be cut by the LIG- 34 meganuclease inside of the cell to separate the two cassettes from one another.
  • the LIG-34 expression cassette and the nonhomologous donor cassette are delivered simultaneously to individual maize cells or maize embryos.
  • the LIG-34 expression cassette is delivered first to individual maize cells or maize embryos and the homologous donor cassette is delivered subsequently to the same cell or embryo.
  • Transformed cells are then grown into calli or plants and are screened (e.g., by PCR) for individuals in which the sequence of interest integrated into the LIG-34 recognition site by non-homologous end-joining.
  • the sequence of interest is a selectable marker gene (e.g., an herbicide resistance gene) and transformed plants can be selected for under the appropriate growth conditions (e.g., in the presence of herbicide) followed by molecular screening to identify individuals in which the sequence of interest integrated at the LIG-34 recognition site.
  • a selectable marker gene e.g., an herbicide resistance gene
  • LIG-34 meganuclease in a maize plant see Fig. 10 and Example 6, pgs. 70-77 of WO/2009/006297, which are incorporated by reference herein. This demonstrates the in vivo activity of LIG34 meganucleases and their usefulness for genetic engineering of plants such as maize.
  • Example 1 In vitro DNA cleavage activity of the LIG-34 meganucleases.
  • SEQ ID NO: 12 were assembled by PCR and cloned into a bacterial expression vector (pET-21a, Novagen Corp., San Diego, CA) with a C-terminal 6X-his tag to facilitate purification.
  • the plasmids were then used to transform chemically competent BL21 (DE3) pLysS E. coli, which were plated on standard 2xYT plates containing 200 ⁇ g/ml carbanicillin. Following overnight growth, transformed bacterial colonies were scraped from the plates and used to inoculate 50 ml of 2XYT broth. Cells were grown at 37°C with shaking until they reached an optical density of 0.6-0.8 at a wavelength of 600 nm.
  • the growth temperature was then reduced from 37°C to 25°C.
  • Protein expression was induced by the addition of 1 mM IPTG, and the cells were incubated with agitation for three hours. Cells were then pelleted by centrifugation for 10 min. at 6000 x g. Pellets were resuspended in 1 ml binding buffer (20 mM Tris-HCL, pH 8.0, 500 mM NaCl, 10 mM imidazole) by vortexing. The cells were then disrupted with 12 pulses of sonication at 50% power and the cell debris was pelleted by centrifugation for 15 min. at 14,000 x g. Cell supernatants were diluted in 4 ml binding buffer and loaded onto a 200 ⁇ l nickel-charged metal-chelating Sepharose column (Pharmacia).
  • the enzymes were exchanged into SA buffer (25 mM Tris-HCL, pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 5mM EDTA) for assays and storage using Zeba spin desalting columns (Pierce Biotechnology, Inc., Rockford, IL).
  • SA buffer 25 mM Tris-HCL, pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 5mM EDTA
  • SA buffer 25 mM Tris-HCL, pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 5mM EDTA
  • SA buffer 25 mM Tris-HCL, pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 5mM EDTA
  • the enzyme concentration was determined by absorbance at 280 nm using an extinction coefficient of 47180 M 1 Cm "1 . Purity and molecular weight of the enzymes was
  • the LIG-34 meganucleases were assayed for in vitro activity by incubation with linear, double-stranded DNA substrates containing the meganuclease recognition sequence.
  • Synthetic oligonucleotides corresponding to both sense and antisense strands of the LIG-34 recognition site (SEQ ID NO: 2, SEQ ID NO: 3) were annealed and cloned into the Smal site of the pUC19 plasmid by blunt-end ligation.
  • the plasmid substrate was linearized with Xmnl concurrently with the meganuclease digest.
  • the enzyme digests contained 5 ⁇ l of 0.05 ⁇ M DNA substrate, 5 ⁇ l of meganuclease at varying concentrations (diluted in SA buffer, see below), 14.5 ⁇ l SA buffer, and 0.5 ⁇ lXmnl. LIG-34 enzyme concentration was varied from 5-400 nM (final concentration). Digests were incubated at 37°C for 1 hour. Digests were stopped by adding 0.3 mg/ml Proteinase K and 0.5% SDS, and incubated for one hour at 37°C. Digests were analyzed on 1.5% agarose and visualized by ethidium bromide staining.
  • Example 2 In vivo DNA cleavage activity of the LIG-34 meganucleases.
  • LIG-34, LIG-34+, and LIG-34++ were evaluated for DNA cleavage activity in a reporter assay in a human cell-line as follows: a defective GFP reporter cassette was generated by first cloning a 5' 480 bp fragment of the GFP gene into Mzel/Hmdlll-digested pcDNA5/Fi?r(Invitrogen Corp., Carlsbad, CA, USA) resulting in the plasmid, pGF. Next, a 3' 480 fragment of the GFP gene (including a 240 bp sequence duplicated in the 5' 480 bp fragment) was cloned into 5 ⁇ mHI/A7zoI-digested pGF.
  • pGFFP The resulting plasmid, pGFFP, consists of the 5' 2/3 rd of the GFP gene followed by the 3' 2/3 rd of the GFP gene, interrupted by 24 bp of the pcDNA5/FRT polylinker.
  • LIG-34 recognition site To insert the LIG-34 recognition site into pGFFP, complimentary oligonucleotides encoding the binding site were annealed and ligated into HmdIII/i? ⁇ mHI-digested pGFFP, resulting in pGFFP.LIG34.
  • This plasmid comprises, in 5' to 3' orientation: a CMV promoter, the 5' 2/3 of the GFP gene, a LIG-34 recognition site sequence, the 3' 2/3 of the GFP gene, and a BGH polyadenylation signal.
  • a CMV promoter the 5' 2/3 of the GFP gene
  • a LIG-34 recognition site sequence the 3' 2/3 of the GFP gene
  • a BGH polyadenylation signal In vivo cleavage of the LIG-34 site by the LIG-34 meganuclease is expected to stimulate homologous recombination between the two direct repeats of the GFP gene to yield a functional GFP gene ( Figure 2). 293.
  • LIG34 cells were generated by stably integrating this reporter cassette into the genome of FIp-In 293 cells using the FIp-In system according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA).
  • LIG-34, LIG-34+, and LIG-34++ were inserted into to the mammalian expression vector pCI (Promega) under the control of a constitutive (CMV) promoter. 293.GFFP.LIG34 cells at -90% confluence were transfected in 24-well plates with either 800 ng pCI GFP (to determine transfection efficiency), 800 ng empty pCI (no enzyme control) or 400 ng pCI encoding LIG-34, LIG-34+, or LIG-34++ balanced with 400 ng empty pCI, using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a rationally-designed, non-naturally- occurring meganuclease with altered DNA recognition sequence specificity which recognizes and cleaves a unique DNA site in the maize genome. The invention also relates to methods of producing engineered maize plants using such meganuc leases.

Description

RATIONALLY-DESIGNED MEGANUCLEASES FOR MAIZE GENOME ENGINEERING
FIELD OF THE INVENTION
[0001] The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a rationally-designed, non- naturally-occurring meganuclease with altered DNA recognition sequence specificity which recognizes and cleaves a unique DNA site in the maize genome. The invention also relates to methods of producing engineered maize plants using such meganucleases.
BACKGROUND OF THE INVENTION
[0002] Genome engineering requires the ability to insert, delete, substitute and otherwise manipulate specific genetic sequences within a genome, and has numerous therapeutic and biotechno logical applications. The development of effective means for genome modification remains a major goal in gene therapy, agrotechnology, and synthetic biology (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73; Tzfira et al. (2005), Trends Biotechnol. 23: 567-9; McDaniel et al. (2005), Curr. Opin. Biotechnol. 16: 476-83). A common method for inserting or modifying a DNA sequence involves introducing a transgenic DNA sequence flanked by sequences homologous to the genomic target and selecting or screening for a successful homologous recombination event. Recombination with the transgenic DNA occurs rarely but can be stimulated by a double-stranded break in the genomic DNA at the target site. Numerous methods have been employed to create DNA double-stranded breaks, including irradiation and chemical treatments. Although these methods efficiently stimulate recombination, the double-stranded breaks are randomly dispersed in the genome, which can be highly mutagenic and toxic. At present, the inability to target gene modifications to unique sites within a chromosomal background is a major impediment to successful genome engineering.
[0003] One approach to achieving this goal is stimulating homologous recombination at a double-stranded break in a target locus using a nuclease with specificity for a sequence that is sufficiently large to be present at only a single site within the genome (see, e.g. , Porteus et al. (2005), Nat. Biotechnol. 23: 967-73). The effectiveness of this strategy has been demonstrated in a variety of organisms using chimeric fusions between an engineered zinc finger DNA-binding domain and the non-specific nuclease domain of the Fokl restriction enzyme (Porteus (2006), MoI Ther 13: 438-46; Wright et al. (2005), Plant J. AA: 693-705; Urnov et al. (2005), Nature 435: 646-51). Although these artificial zinc finger nucleases stimulate site-specific recombination, they retain residual non-specific cleavage activity resulting from under-regulation of the nuclease domain and frequently cleave at unintended sites (Smith et al. (2000), Nucleic Acids Res. 28: 3361-9). Such unintended cleavage can cause mutations and toxicity in the treated organism (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73).
[0004] A group of naturally-occurring nucleases which recognize 15-40 base-pair cleavage sites commonly found in the genomes of plants and fungi may provide a less toxic genome engineering alternative. Such naturally-occurring "meganucleases" or "homing endonucleases" are frequently associated with parasitic DNA elements, such as group I self- splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), Q. Rev. Biophys. 38: 49-95). Meganucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The LAGLIDADG meganucleases with a single copy of the LAGLIDADG motif form homodimers, whereas members with two copies of the LAGLIDADG motif are found as monomers. Similarly, the GIY-YIG family members have a GIY-YIG module, which is 70-100 residues long and includes four or five conserved sequence motifs with four invariant residues, two of which are required for activity (see Van Roey et al. (2002), Nature Struct. Biol. 9: 806-811). The His-Cys box meganucleases are characterized by a highly conserved series of histidines and cysteines over a region encompassing several hundred amino acid residues (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). In the case of the NHN family, the members are defined by motifs containing two pairs of conserved histidines surrounded by asparagine residues (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The four families of meganucleases are widely separated from one another with respect to conserved structural elements and, consequently, DNA recognition sequence specificity and catalytic activity. [0005] Naturally-occurring meganucleases, primarily from the LAGLIDADG family, have been used to effectively promote site-specific genome modification in plants, yeast, Drosophila, mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that conserve the meganuc lease recognition sequence (Monnat et al. (1999), Biochem. Biophys. Res. Commun. 255: 88-93) or to pre- engineered genomes into which a recognition sequence has been introduced (Rouet et al. (1994), MoI. Cell. Biol. 14: 8096-106; Chilton et al. (2003), Plant Physiol. 133: 956-65; Puchta et al. (1996), Proc. Natl. Acad. Sci. USA 93: 5055-60; Rong et al. (2002), Genes Dev. 16: 1568-81; Gouble et al. (2006), J. Gene Med. 8(5):616-622).
[0006] Systematic implementation of nuc lease-stimulated gene modification requires the use of engineered enzymes with customized specificities to target DNA breaks to existing sites in a genome and, therefore, there has been great interest in engineering meganucleases to promote gene modifications at medically or biotechnologically relevant sites (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73; Sussman et al. (2004), J. MoI. Biol. 342: 31-41; Epinat et al. (2003), Nucleic Acids Res. 31 : 2952-62).
[0007] The meganuclease I-Crel from Chlamydomonas reinhardtii is a member of the
LAGLIDADG family which recognizes and cuts a 22 base-pair recognition sequence in the chloroplast chromosome, and which presents an attractive target for meganuclease redesign. The wild-type enzyme is a homodimer in which each monomer makes direct contacts with 9 base pairs in the full-length recognition sequence. Genetic selection techniques have been used to identify mutations in I-Crel that alter base preference at a single position in this recognition sequence (Sussman et al. (2004), J. MoI. Biol. 342: 31-41; Chames et al. (2005), Nucleic Acids Res. 33: el78; Seligman et al. (2002), Nucleic Acids Res. 30: 3870-9) or, more recently, at three positions in the recognition sequence (Arnould et al. (2006), J. MoI. Biol. 355: 443-58). The I-Crel protein-DNA interface contains nine amino acids that contact the DNA bases directly and at least an additional five positions that can form potential contacts in mutant interfaces. The size of this interface imposes a combinatorial complexity that is unlikely to be sampled adequately in sequence libraries constructed to select for enzymes with drastically altered cleavage sites.
[0008] There remains a need for nucleases that will facilitate precise modification of a genome by cleaving any desired genomic sequence, including sequences not cleaved by naturally-occurring homing endonucleases. This is particularly true of the agriculture industry in which the production of genetically modified crop lines is significantly hindered by the current inability to target the insertion or removal of nucleic acids from specific regions of the genome. The present invention provides, inter alia, an engineered meganucleases which recognize a unique DNA sequence found in the Zea mays (maize) genome and methods for using these engineered meganucleases to precisely target the insertion of nucleic acids into the maize genome.
SUMMARY OF THE INVENTION
[0009] The present invention relates to certain engineered meganucleases ("LIG-34 meganucleases") which recognize and cut a 22 basepair DNA sequence found in the genome of Zea mays (maize). The invention provides a composition comprising a LIG34 meganuclease, a maize plant comprising an exogenous DNA sequence in its chromosome, as well as methods that use LIG34 meganucleases to target the insertion of nucleic acids into a specific locus in the maize genome.
[0010] In one aspect, the invention provides a rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 1. In another aspect, the invention provides a rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 12. In yet another aspect, the invention provides a rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 13.
[0011] In one aspect, the invention provides a rationally-designed meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3.
[0012] In another aspect, the invention provides a method for the production of a recombinant maize plant in which a sequence of interest is integrated the maize genome, the method comprising transforming a maize cell or embryo with: (a) a first DNA molecule comprising: a DNA sequence encoding a meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3; and a promoter suitable for the expression of such a meganuclease in maize; and (b) a second DNA molecule comprising a sequence of interest.
[0013] In yet another aspect, the invention provides a method for the production of a recombinant maize plant in which a sequence of interest is integrated the maize genome, the method comprising transforming a maize cell or embryo with: (a) a first DNA molecule comprising: a DNA sequence encoding a meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3; and a promoter suitable for the expression of such a meganuclease in maize; and (b) a second DNA molecule comprising: a sequence of interest flanked on one side by a DNA sequence with homology to 50-900 consecutive base pairs of SEQ ID NO: 10 and flanked on the other side by a DNA sequence with homology to 50-900 consecutive base pairs of SEQ ID NO: 11.
[0014] The sequence of interest can be flanked on at least one side by the first nine nucleotides from the meganuclease recognition sequence of SEQ ID NO: 2 or SEQ ID NO: 3. The maize cell or embryo can be transformed with a molecule comprising the first DNA molecule and the second DNA molecule. The maize cell or embryo can be transformed with a molecule comprising the first DNA molecule and the second DNA molecule and wherein SEQ ID NO: 2 or SEQ ID NO: 3 is located between the DNA sequence encoding the meganuclease and the sequence of interest.
[0015] In one aspect, the invention provides a maize plant with a chromosome comprising a composite sequence, the composite sequence comprising: a sequence of interest; a first sequence comprising 50-900 base pairs from SEQ ID NO: 10 immediately upstream of the sequence of interest; and a second sequence comprising 50-900 base pairs from SEQ ID NO: 11 immediately downstream of the sequence of interest. The sequence of interest can comprise an exogenous gene.
[0016] In some embodiments of the maize plant, the composite sequence is free of retroviral sequences, Agrobacterium tumefaciens sequences and/or transposon sequences. In some embodiments, the maize plant has a single composite sequence in said chromosome. [0017] In some embodiments of the maize plant, the 3' nucleotide of the first sequence corresponds to a nucleotide selected from the group consisting of nucleotides 950- 961 of SEQ ID NO: 10. In some embodiments of the maize plant, the 5' nucleotide of the second sequence corresponds to a nucleotide selected from the group consisting of nucleotides 1-11 of SEQ ID NO: 11.
[0018] In one aspect, the invention provides a maize plant having a sequence of interest inserted in its chromosome, wherein the sequence of interest is inserted into SEQ ID NO: 2 and SEQ ID NO: 3. [0019] In some embodiments, the sequence of interest is inserted only once into said chromosome. The sequence of can interest can comprise an exogenous gene.
BRIEF DESCRIPTION OF THE FIGURES
[0020] Figure 1 illustrates the interactions between the LIG-34 meganuclease and its double-stranded recognition sequence found in the maize genome. This schematic representation depicts the recognition sequence (SEQ ID NO: 2 and SEQ ID NO: 3), shown as unwound for illustration purposes only, bound by the LIG-34 meganuclease. The N- and C-terminal domains of LIG-34 are shown as two ovals. The bases of each DNA half-site are numbered -1 through -9, and the amino acid residues of LIG-34 which form the recognition surface are indicated by one-letter amino acid designations and numbers indicating residue position. Amino acids with asterisks are mutant relative to wild-type I-Crel. Solid black lines: hydrogen bonds and hydrophobic contacts to DNA bases. Arrows: residues that interact with the DNA backbone and influence cleavage activity.
[0021] Figure 2 is a schematic of a direct-repeat recombination assay used to evaluate the LIG-34 meganucleases. To perform this assay, as described in detail in Example 2, a defective GFP reporter gene was stably integrated into the chromosomal DNA of a human (HEK-293) cell-line. The gene is interrupted by a LIG-34 recognition site which is flanked by -250 base pairs of directly repeated sequence of the GFP gene. This reporter cell-line is then transfected with a mammalian expression vector carrying a LIG-34 meganuclease gene and in vivo cleavage of the LIG-34 site by the meganuclease stimulates homologous recombination between direct repeats of the GFP gene, which results in a functional GFP (GFP+) coding sequence. GFP+ cells can then be counted by flow cytometry. [0022] Figure 3 is a bar graph representation of the results of the assay described in
Figure 2 to evaluate the LIG-34, LIG-34+, and LIG-34++ meganucleases. The three meganucleases produced GFP+ cells with frequencies of 2.5%, 5.3%, and 7.1%, respectively, while an empty expression vector yielded <0.1% GFP+ cells. DETAILED DESCRIPTION OF THE INVENTION
1.1 Introduction
[0023] The present invention provides engineered meganucleases which specifically recognize and cleave a 22 bp, double-stranded DNA sequence found in the maize genome, that has the sequence shown in SEQ ID NO: 2 and SEQ ID NO: 3, and which is referred to herein as the "LIG-34 recognition site." These meganucleases are produced, in part, in accordance with the methods disclosed in WO 2007/047859. Examples of such meganucleases include those designated herein as "LIG-34" (SEQ ID NO: 1), "LIG-34+" (SEQ ID NO: 12) and "LIG-34++" (SEQ ID NO: 13). The disclosure of WO 2007/047859, which is incorporated herein by reference, describes a method for the production of meganucleases derived from the natural I-Crel homing endonuclease, but that recognize DNA sequences that differ from the sequence recognized by wild-type I-Crel. The LIG-34, LIG-34+, LIG-34++ meganucleases, as well as other meganucleases produced according to the methods disclosed in WO 2007/047859, and that recognize and cleave the LIG-34 recognition site, are collectively referred to herein as "LIG34 meganucleases." [0024] The LIG-34 meganucleases can be used for cleaving a unique DNA site in the genome of Zea mays and thereby enable gene insertion at that site in the genome. This invention will have a significant impact on the agriculture industry as it allows seed producers to generate transgenic maize plants in which trait genes of agronomic value (e.g., herbicide resistance genes, insect resistance genes, drought tolerance genes, disease resistance genes, and genes affecting yield or fertility) are inserted precisely at the LIG-34 recognition site. Although methods for incorporating transgenes into the maize genome are well known in the art (e.g., Agrobacterium-mediatGd transformation, particle-bombardment, "whiskers" transformation, and lipofection) these methods integrate transgenes at more-or- less random locations in the genome. The ability to target transgene insertion to the LIG-34 recognition site has numerous advantages over these existing methods. First, it enables transgenes to be inserted into a region of the genome with known gene expression characteristics. Second, it enables the repeated targeting of trait genes to the same genomic locus, which will accelerate regulatory approval of subsequent genetically modified maize products following a first approval. Lastly, it enables multiple genes to be inserted adjacent to one another in the same region of the genome so that they are genetically linked and will consistently co-segregate throughout subsequent breedings. [0025] Thus, in one embodiment, this invention provides a LIG-34 meganuclease. In another embodiment, it provides methods for using a LIG-34 meganuclease to insert transgenes into the maize genome at the LIG-34 recognition site.
1.2 References and Definitions
[0026] The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. The issued U.S. patents, allowed applications, published foreign applications, and references, including GenBank database sequences, that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. [0027] As used herein, the term "meganuclease" refers to a naturally-occurring homing endonuclease that binds double-stranded DNA at a recognition sequence that is greater than 12 base pairs and encompasses the corresponding intron insertion site. Naturally-occurring meganucleases can be monomeric (e.g., I-Scel) or dimeric (e.g., I-Crel). The term meganuclease, as used herein, can be used to refer to monomeric meganucleases, dimeric meganucleases, or to the monomers which associate to form a dimeric meganuclease. [0028] As used herein, the term "rationally-designed" means non-naturally occurring and/or genetically engineered. The rationally-designed meganucleases of the invention differ from wild-type or naturally-occurring meganucleases in their amino acid sequence or primary structure, and may also differ in their secondary, tertiary or quaternary structure. In addition, the rationally-designed meganucleases of the invention also differ from wild-type or naturally-occurring meganucleases in recognition sequence-specificity and/or activity. [0029] As used herein, with respect to a protein, the term "recombinant" means having an altered amino acid composition as a result of the application of genetic engineering techniques to nucleic acids which encode the protein, and cells or organisms which express the protein. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion. In accordance with this definition, a protein having an amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous different host, is not considered recombinant.
[0030] As used herein, the term "genetically-modified" refers to a cell or organism in which, or in an ancestor of which, a genomic DNA sequence has been deliberately modified by recombinant technology. As used herein, the term "genetically-modified" encompasses the term "transgenic."
[0031] As used herein, the term "wild-type" refers to any naturally-occurring form of a meganuclease. The term "wild-type" is not intended to mean the most common allelic variant of the enzyme in nature but, rather, any allelic variant found in nature. Wild-type meganucleases are distinguished from recombinant or non-naturally-occurring meganucleases.
[0032] As used herein, the term "recognition sequence half-site" or simply "half site" means a nucleic acid sequence in a double-stranded DNA molecule which is recognized by a monomer of a mono-LAGLID ADG meganuclease or by one LAGLIDADG subunit of a di- LAGLIDADG meganuclease.
[0033] As used herein, the term "recognition sequence" refers to a pair of inverted half-sites separated by four base pairs, which is bound and cleaved by either a mono- LAGLID ADG meganuclease dimer or a di-LAGLIDADG meganuclease monomer. In the case of I-Crel, the recognition sequence half-site of each monomer spans 9 base pairs, and the two half-sites are separated by four base pairs, designated Ni through N4, which are not recognized specifically. Thus, the combined recognition sequence of the I-Crel meganuclease dimer normally spans 22 base pairs, including the 9 base pairs 5' of the central N1-N4 bases on the sense strand, which are designated -9 through -1, the central Ni-N4 base pairs, and the 9 base pairs 3' of the central Ni-N4 bases on the sense strand, which are designated -1 through -9.
[0034] As used herein, the term "specificity" means the ability of a meganuclease to recognize and cleave double-stranded DNA molecules only at a particular sequence of base pairs referred to as the recognition sequence, or only at a particular set of recognition sequences. The set of recognition sequences will share certain conserved positions or sequence motifs, but may be degenerate at one or more positions. A highly-specific meganuclease is capable of cleaving only one or a very few recognition sequences. [0035] As used herein, the term "palindromic" refers to a recognition sequence consisting of inverted repeats of identical half-sites. In this case, however, the palindromic sequence need not be palindromic with respect to the four central nucleotide pairs, which are not contacted by the enzyme. In the case of dimeric meganucleases, palindromic DNA sequences are recognized by homodimers in which the two monomers make contacts with identical half-sites. [0036] As used herein, the term "pseudo-palindromic" refers to a recognition sequence consisting of inverted repeats of non-identical or imperfectly palindromic half- sites. In this case, the pseudo-palindromic sequence not only need not be palindromic with respect to the four central nucleotide pairs, but also can deviate from a palindromic sequence between the two half- sites. Pseudo-palindromic DNA sequences are typical of the natural DNA sites recognized by wild-type homodimeric meganucleases in which two identical enzyme monomers make contacts with different half- sites.
[0037] As used herein, the term "non-palindromic" refers to a recognition sequence composed of two unrelated half-sites of a meganuc lease. In this case, the non-palindromic sequence need not be palindromic with respect to either the four central nucleotide pairs or the two monomer half- sites. Non-palindromic DNA sequences are recognized by either highly degenerate meganucleases (e.g., I-Ceul) or by heterodimers of meganuclease monomers that recognize non-identical half- sites.
[0038] As used herein, the term "activity" refers to the rate at which a meganuclease of the invention cleaves a particular recognition sequence. Such activity is a measurable enzymatic reaction, involving the hydrolysis of phosphodiester bonds of double-stranded DNA. The activity of a meganuclease acting on a particular DNA substrate is affected by the affinity or avidity of the meganuclease for that particular DNA substrate which is, in turn, affected by both sequence-specific and non-sequence-specific interactions with the DNA. [0039] As used herein, the term "LIG-34 recognition site" refers to a region of the maize genome approximately 1200 basepairs 5' of the LIGULESSl gene (genbank accession # AF451895) which contains the 22 bp DNA sequence recognized by the LIG-34 meganuclease (SEQ ID NO: 2 and SEQ ID NO: 3).
2. The LIG-34 meganuclease.
[0040] The LIG-34 meganuclease is a derivative of I-Crel that is genetically engineered with respect to its DNA cleavage specificity in accordance with the method disclosed in WO/2007/047859. The amino acid substitutions that were introduced into the LIG-34 meganuclease for the purpose of altering DNA cleavage specificity are diagrammed in Figure 1 and listed in Table 1. Because LIG-34 is a single-chain heterodimeric meganuclease whereas I-Crel is a homodimer and because the LIG-34 meganuclease has an N-terminal nuclease localization signal (as discussed below) the amino acid numbering differs from wild-type I-Crel. Table 1, therefore, also lists the corresponding DNA contacting residue in the amino acid sequence of wild-type I-Crel (SEQ ID NO: 4). [0041] Table 1. Mutations in LIG-34 which alter DNA-cleavage specificity relative to wild-type I-Crel.
Figure imgf000012_0001
[0042] In addition to the amino acid substitutions listed in Table 1 which were designed to control DNA-cleavage specificity, LIG-34 endonucleases may incorporate additional amino acid substitutions intended to increase the overall cleavage activity of the meganuclease (Table 2). In the cases of 187 and T239, the activity of the LIG-34 meganuclease is increased by reverting negatively-charged amino acids, which were introduced to alter cleavage specificity (E87 and E239, see Table 1) back to the wild-type amino acid. The net effect is a reduction in the overall specificity of the endonuclease, but an increase in endonuclease activity due to the removal of negative charges (which repulse the negatively charged DNA and, thereby, reduce DNA-binding affinity) from the protein-DNA interface. In the cases of Q90 and Q277, the incorporation of glutamine at these amino acid positions, whereas wild-type I-Crel has glutamic acid in the corresponding position, eliminates electrostatic repulsion between the negatively-charged glutamic acid sidechain and the negatively-charged DNA. The effect of this pair of substitutions is that the overall DNA binding affinity of the engineered meganuclease is increased with a corresponding increase in the cleavage activity. In the cases of C89 and C276, the introduction of cysteine at these positions, whereas wild-type I-Crel has a serine in the corresponding position, increases the endonuclease affinity for DNA (and, hence, DNA cleavage activity), presumably through a favorable van der Waals interaction with the DNA backbone. The remaining amino acid substitutions listed in Table 2 convert an uncharged amino acid (Y66, 181, and/or Pl 13) to a positively-charged amino acid (K or R). All of these substitutions are believed to introduce favorable electrostatic interactions between the positively-charged amino acid sidechain and the negatively-charged phosphate backbone of the DNA. Again, the net effect is to increase the DNA-binding affinity which increases cleavage activity.
[0043] Table 2. Mutations in LIG-34 which increase DNA-cleavage activity
Figure imgf000013_0001
[0044] The introduction of some or all of the modifications listed in Table 2 is useful to restore the level of cleavage activity that is lost upon introducing the mutations listed in Table 1 so that the LIG-34 meganuclease maintains the ability to cleave DNA at a rate that is comparable to wild-type I-Crel. Thus, the invention provides a family of engineered meganucleases which cleave the LIG-34 recognition sequence (SEQ ID NO: 2 and SEQ ID NO: 3), but do so with varying degrees of endonuclease activity and/or specificity due to different combinations of the mutations listed in Table 2. For example, one preferred embodiment of LIG-34 is SEQ ID NO: 1, which incorporates the mutations listed in Table 1 as well as Q90 and Q277 from Table 2. A second preferred embodiment is SEQ ID NO: 12, referred to as "LIG-34+", which incorporates the mutations listed in Table 1 as well as Q90, Q277, and T239 (which is a reversion back to a wild-type amino acid). LIG-34+ cleaves the LIG-34 recognition sequence more efficiently in vitro as well as inplanta relative to SEQ ID NO: 1, but has slightly reduced specificity relative to SEQ ID NO: 1. A third preferred embodiment is SEQ ID NO: 13, referred to as "LIG-34++" which incorporates the mutations listed in Table 1 as well as Q90, Q277, C89, 187, and T239 (the latter two are reversions back to a wild-type amino acid). LIG-34++ cleaves the LIG-34 recognition sequence more efficiently in vitro and inplanta than SEQ ID NO:1 and SEQ ID NO: 12, but has reduced specificity relative to SEQ ID NO:1 and SEQ ID NO: 12.
[0045] As discussed in WO/2007/047859, wild-type I-Crel binds to and cleaves DNA as a homodimer. As a consequence, the natural recognition sequence for I-Crel (SEQ ID NO: 5, SEQ ID NO: 6) is pseudo-palindromic. The LIG-34 recognition sequence (SEQ ID NO: 2, SEQ ID NO: 3), however, is non-palindromic. This necessitates the use of an engineered meganuclease heterodimer comprising a pair of subunits each of which recognizes one half-site within the full-length recognition sequence. In the case of LIG-34, the two engineered meganuclease monomers are physically linked to one another using an amino acid linker to produce a single-chain heterodimer. This linker comprises amino acids 166-204 (SEQ ID NO: 7) of LIG-34. The linker sequence joins an N-terminal meganuclease subunit terminated at L 165 (corresponding to L 155 of wild-type I-Crel) with a C-terminal meganuclease subunit starting at K204 (corresponding to K7 of wild-type I-Crel). The benefits of physically linking the two meganuclease monomers using this novel linker are twofold: first, it ensures that the meganuclease monomers can only associate with one another (heterodimerize) to cut the non-palindromic LIG-34 recognition sequence rather than also forming homodimers which can recognize palindromic or pseudopalindromic DNA sites that differ from the LIG-34 recognition sequence. Second, the physical linking of meganuclease monomers obviates the need to express two monomers simultaneously in the same cell to obtain the desired heterodimer. This significantly simplifies vector construction in that it only requires a single gene expression cassette.
[0046] Lastly, the LIG-34 meganuclease incorporates an N-terminal nuclear localization signal (NLS, SEQ ID NO: 7) derived from the mammalian SV40 virus. This peptide leader sequence was added to direct the LIG-34 meganuclease to the nucleus of a maize cell. The use of the SV40 NLS sequence is common in the art. [0047] The LIG-34 meganucleases of SEQ ID NO: 1, SEQ ID NO: 12, and SEQ ID
NO: 13 have been evaluated using an in vitro DNA cleavage assay and were found to cleave the LIG-34 recognition sequence with efficiency comparable to or better than wild-type I- Crel, as shown in Example 1. 3. Methods of Producing Recombinant Maize Using the LIG-34 Meganuclease [0048] Aspects of the present invention further provide methods for producing recombinant, transgenic or otherwise genetically-modified maize cells and plants using LIG- 34 (uses for LIG-34 are also discussed in WO 2009/006297). Thus, in one embodiment, the LIG-34 meganuclease is used to cause a double-stranded break at the LIG-34 recognition site to allow for precise insertion(s) of a sequence of interest into that site by homologous recombination. In another embodiment, the LIG-34 meganuclease is used to cause a double- stranded break at the LIG-34 recognition site to allow for precise insertion(s) of a sequence of interest into that site by non-homologous end-joining.
[0049] As used herein, the term "sequence of interest" means any DNA sequence that can be inserted into the maize genome. Sequences of interest will typically be genes that confer commercially valuable traits to maize plants (e.g., genes that confer herbicide resistance, genes that confer insect resistance, genes that confer disease resistance, genes that confer drought resistance, genes that improve nutritional value, genes that improve yield or quality, and genes that affect plant fertility) as well as transcription regulation sequences (e.g., a promoter and transcription terminator) to control expression of the trait gene. These regulatory sequences include, but are not limited to, constitutive plant promoters such as the NOS promoter, The 35S promoter, or the UBI promoter, chemically-inducible gene promoters such as the dexamethasone-inducible promoter (see, e.g., Gremillon et αl. (2004), Plant J. 37:218-228), and plant tissue specific promoters such as the LGCl promoter (see, e.g., Singh et al. (2003), FEBS Lett. 542:47-52).
[0050] As used herein, the term "homologous recombination" refers to a natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, e.g., Cahill et al. (2006),Front. Biosci. 11 :1958-1976). Thus, in some embodiments, the LIG-34 meganuclease is used to cleave the LIG-34 recognition site in a maize cell and a sequence of interest flanked by DNA sequence with homology to the LIG-34 recognition site is delivered into a maize cell and used as a template for repair by homologous recombination. The sequence of interest is thereby incorporated into LIG-34 recognition site.
[0051] As used herein, the term "non-homologous end-joining" refers to a natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, e.g., Cahill et al. (2006), Front. Biosci. 11 :1958- 1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the capture of exogenous DNA sequences at the site of repair joining (see, e.g., Salomon, et al. (1998), EMBOJ. 17:6086-6095). This is particularly true of exogenous DNA sequences delivered by Agrobacterium tumefaciens. Thus, in certain embodiments, the LIG-34 meganuclease can be used to produce a double-stranded break at the LIG-34 recognition site in a maize cell and a sequence of interest, which may or may not have homology to the LIG- 34 recognition site, can be delivered to a maize cell and be captured at the LIG-34 site by non-homologous end-joining. The sequence of interest is, thereby, incorporated into the LIG-34 recognition site.
[0052] As a general matter, methods for delivering nucleic acids to maize cells are well known in the art and include Agrobacterium infection, PEG-mediated transformation of protoplasts (Omirulleh et al. (1993), Plant Molecular Biology, 21 :415-428), desiccation/inhibition-mediated DNA uptake, electroporation, agitation with silicon carbide fibers, ballistic injection or microprojectile bombardment, biolistic injection (Lorence and Verpoorte (2004), Methods MoI. Biol., 267: 329-50) and the like. Also, as a general rule, the method of gene delivery can be correlated with the activity level of the LIG-34 meganuclease. Meganucleases with lower activity (e.g., SEQ ID NO: 1) are advantageously delivered by Agrobacterium infection or a related method which efficiently produces stable transformants (i.e. produces plants in which the LIG-34 gene is integrated stably into the plant genome). This is because long-term exposure to meganuclease is more likely to yield high-efficiency DNA cleavage by such reduced-activity meganucleases. On the other hand, microprojectile bombardment of plasmid DNA, biolistic injection, or similar methods which can result in transient gene delivery (i.e. the meganuclease gene is NOT integrated into the genome and is NOT selected for and, thus, is lost over time) are advantageous for delivering very high activity LIG-34 meganucleases (such as SEQ ID NO: 13) because long-term exposure to a high-activity LIG-34 meganuclease is not necessary for high-efficiency cleavage of the LIG-34 recognition sequence and may lead to toxicity due to off-target DNA cleavage.
[0053] In some embodiments, the methods of the invention involve the delivery of a sequence of interest as well as the gene encoding the LIG-34 meganuclease into a single maize cell or embryo which can be grown into a mature recombinant maize plant and give rise to progeny carrying the inserted sequence of interest in its genome. 3.1 Methods for Inserting a Sequence of Interest into the LIG-34 Recognition Site by Homologous Recombination.
[0054] Aspects of the invention allow for the use of the LIG-34 meganuc lease to introduce a sequence of interest into the LIG-34 recognition site by homologous recombination. Such methods require two components:
[0055] 1. The LIG-34 expression cassette. This component is a DNA molecule encoding the LIG-34 meganuclease under the control of a promoter suitable for the expression of the meganuclease gene in a maize cell. Such promoters are known in the art and include, preferably, constitutive plant promoters such as the nopaline synthase (nos) promoter, the CaMV 35 S promoter, or the plant ubiquitin (Ubi) promoter. In addition, for some embodiments, chemically-inducible gene promoters such as the dexamethasone- inducible promoter (see, e.g., Gremillon et al. (2004), Plant J. 37:218-228), and plant tissue specific promoters such as the LGCl promoter (see, e.g., Singh et al. (2003), FEBS Lett. 542:47-52) may be used. In general, the choice of promoter may be correlated with the activity level of the LIG-34 meganuclease and/or choice of gene delivery method. For example, strong, constitutive promoters such as Ubi or CaMV 35S are preferred for low- activity LIG-34 meganucleases (such as SEQ ID NO: 1) and for applications in which the meganuclease gene is delivered transiently (such as microprojectile bombardment in the absence of selection for stable transformants). On the other hand, inducible promoters, tissue-specific promoters, or weak constitutive promoters are preferred for high-activity meganucleases (such as SEQ ID NO: 13) in cases where the meganuclease expression cassette is stably integrated into the plant genome for long-term expression of the meganuclease gene. Preferably, the LIG-34 meganuclease coding sequence will be optimized for expression in eukaryotic cells {e.g., SEQ ID NO: 9). Also preferably, the LIG- 34 gene will be followed by a transcription terminator sequence such as the nopaline synthase (nos) terminator.
[0056] 2. The homologous donor cassette. This component is a DNA molecule harboring a sequence of interest flanked on one or, preferably, both sides by regions of homology to the LIG-34 recognition site. The region(s) of homology will be at least 50 base pairs in length and can be, 50-900, 50-1000, 500-900, or 500-1000 base pairs in length. In preferable embodiments, the sequence of interest will be flanked on one side by 50-900, 50- 1000, 500-900, or 500-1000 bases that are identical or nearly identical to the DNA sequence immediately 5' of the LIG-34 recognition sequence (including the 5' LIG-34 recognition half-site) and will be flanked on the other side by 50-900, 50-1000, 500-900, or 500-1000 bases that are identical or nearly identical to the DNA sequence immediately 3' of the LIG-34 recognition sequence (including the 3' LIG-34 recognition half-site). For example, an effective donor cassette may have the following composition: 5'-[50-9OO consecutive base pairs SEQ ID NO: 10] - [sequence of interest] - [50-900 consecutive base pairs SEQ ID NO: 11] - 3'. In another example, an effective donor cassette may have the following composition: 5'-[50-10OO consecutive base pairs SEQ ID NO: 10] - [sequence of interest] - [50-1000 consecutive base pairs SEQ ID NO: 11] - 3'. The homologous donor cassette may or may not be harbored on the same DNA molecule as the LIG-34 expression cassette.
[0057] In preferred embodiments, the LIG-34 expression cassette and the homologous donor cassette are delivered simultaneously to individual maize cells or maize embryos. In other embodiments, the LIG-34 expression cassette is delivered first to individual maize cells or maize embryos and the homologous donor cassette is delivered subsequently to the same cell or embryo. Transformed cells are then grown into calli or plants and are screened (e.g., by PCR) for individuals in which the sequence of interest integrated into the LIG-34 recognition site by homologous recombination or non-homologous end-joining. In certain embodiments, the sequence of interest is a selectable marker gene (e.g., an herbicide resistance gene) and transformed plants can be selected for under the appropriate growth conditions (e.g., in the presence of herbicide) followed by molecular screening to identify individuals in which the sequence of interest integrated at the LIG-34 recognition site.
3.2 Methods for Inserting a Sequence of Interest into the LIG-34 Recognition Site by Non- Homologous End- Joining.
[0058] Aspects of the invention allow for the use of the LIG-34 meganuc lease to introduce a sequence of interest into the LIG-34 recognition site by Non-Homologous End- Joining. Such methods require two components: [0059] 1. The LIG-34 expression cassette. This component is as described in 3.1 above.
2. The non-homologous donor cassette. This component comprises, at a minimum, the sequence of interest with no additional DNA sequence. In some embodiments, the non-homologous donor cassette may comprise the sequence of interest flanked on one or both sides by the LIG-34 recognition sequence. In the latter case, cleavage of the nonhomologous donor cassette by the LIG-34 meganuclease will result in four basepair 3' "sticky ends" on one or both sides of the sequence of interest that are compatible with the sticky ends produced by cleavage of the LIG-34 recognition site which may facilitate integration of the sequence of interest by non-homologous end-joining. The non-homologous donor cassette may be housed on the same DNA molecule as the LIG-34 expression cassette only if the two are separated by a LIG-34 recognition sequence which can be cut by the LIG- 34 meganuclease inside of the cell to separate the two cassettes from one another.
[0060] In preferred embodiments, the LIG-34 expression cassette and the nonhomologous donor cassette are delivered simultaneously to individual maize cells or maize embryos. In other embodiments, the LIG-34 expression cassette is delivered first to individual maize cells or maize embryos and the homologous donor cassette is delivered subsequently to the same cell or embryo. Transformed cells are then grown into calli or plants and are screened (e.g., by PCR) for individuals in which the sequence of interest integrated into the LIG-34 recognition site by non-homologous end-joining. In certain embodiments, the sequence of interest is a selectable marker gene (e.g., an herbicide resistance gene) and transformed plants can be selected for under the appropriate growth conditions (e.g., in the presence of herbicide) followed by molecular screening to identify individuals in which the sequence of interest integrated at the LIG-34 recognition site.
3.3 Methods for Inserting a Sequence of Interest into the LIG-34 Recognition Site by Homologous Recombination In a Maize Plant.
[0061] PCT application WO/2009/006297 describes in vivo activity and uses of the
LIG-34 meganuclease in a maize plant (see Fig. 10 and Example 6, pgs. 70-77 of WO/2009/006297, which are incorporated by reference herein). This demonstrates the in vivo activity of LIG34 meganucleases and their usefulness for genetic engineering of plants such as maize.
EXAMPLES
Example 1: In vitro DNA cleavage activity of the LIG-34 meganucleases.
1. Expression and Purification of LIG-34 meganucleases [0062] Genes encoding LIG-34, LIG-34+, and LIG-34++ (SEQ ID NO: 1, SEQ ID
NO: 12, and SEQ ID NO: 13) were assembled by PCR and cloned into a bacterial expression vector (pET-21a, Novagen Corp., San Diego, CA) with a C-terminal 6X-his tag to facilitate purification. The plasmids were then used to transform chemically competent BL21 (DE3) pLysS E. coli, which were plated on standard 2xYT plates containing 200 μg/ml carbanicillin. Following overnight growth, transformed bacterial colonies were scraped from the plates and used to inoculate 50 ml of 2XYT broth. Cells were grown at 37°C with shaking until they reached an optical density of 0.6-0.8 at a wavelength of 600 nm. The growth temperature was then reduced from 37°C to 25°C. Protein expression was induced by the addition of 1 mM IPTG, and the cells were incubated with agitation for three hours. Cells were then pelleted by centrifugation for 10 min. at 6000 x g. Pellets were resuspended in 1 ml binding buffer (20 mM Tris-HCL, pH 8.0, 500 mM NaCl, 10 mM imidazole) by vortexing. The cells were then disrupted with 12 pulses of sonication at 50% power and the cell debris was pelleted by centrifugation for 15 min. at 14,000 x g. Cell supernatants were diluted in 4 ml binding buffer and loaded onto a 200 μl nickel-charged metal-chelating Sepharose column (Pharmacia).
[0063] The column was subsequently washed with 4 ml wash buffer (20 mM Tris-
HCl, pH 8.0, 500 mM NaCl, 60 mM imidazole) and with 0.2 ml elution buffer (20 mM Tris- HCl, pH 8.0, 500 mM NaCl, 400 mM imidazole). Meganuclease enzymes were eluted with an additional 0.6 ml of elution buffer and concentrated to 50-130 μl using Vivospin disposable concentrators (ISC, Inc., Kaysville, UT). The enzymes were exchanged into SA buffer (25 mM Tris-HCL, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 5mM EDTA) for assays and storage using Zeba spin desalting columns (Pierce Biotechnology, Inc., Rockford, IL). The enzyme concentration was determined by absorbance at 280 nm using an extinction coefficient of 47180 M 1Cm"1. Purity and molecular weight of the enzymes was then confirmed by gel electrophoresis and/or MALDI-TOF mass spectrometry.
2. Cleavage Assays
[0064] The LIG-34 meganucleases were assayed for in vitro activity by incubation with linear, double-stranded DNA substrates containing the meganuclease recognition sequence. Synthetic oligonucleotides corresponding to both sense and antisense strands of the LIG-34 recognition site (SEQ ID NO: 2, SEQ ID NO: 3) were annealed and cloned into the Smal site of the pUC19 plasmid by blunt-end ligation. The plasmid substrate was linearized with Xmnl concurrently with the meganuclease digest. The enzyme digests contained 5 μl of 0.05 μM DNA substrate, 5 μl of meganuclease at varying concentrations (diluted in SA buffer, see below), 14.5 μl SA buffer, and 0.5 μlXmnl. LIG-34 enzyme concentration was varied from 5-400 nM (final concentration). Digests were incubated at 37°C for 1 hour. Digests were stopped by adding 0.3 mg/ml Proteinase K and 0.5% SDS, and incubated for one hour at 37°C. Digests were analyzed on 1.5% agarose and visualized by ethidium bromide staining.
[0065] Digestion of the linearized plasmid with LIG34, LIG34+ or LIG34++ meganuclease produced two bands on the gel of the sizes corresponding to a simple cut at the LIG-34 site. All of the LIG-34 meganucleases efficiently cut the plasmid substrate harboring the LIG-34 recognition site. C50 values (the concentration of meganuclease required to cut 50% of the 1OnM plasmid substrate to completion in 1 hour) were found to be ~16 nM, ~13 nM, and ~11 nM for, respectively, LIG-34, LIG-34+, and LIG-34++. Thus, while all three enzymes efficiently cleave the LIG-34 site sequence, they do so with varying activity levels (LIG-34 < LIG-34+ < LIG-34++).
Example 2: In vivo DNA cleavage activity of the LIG-34 meganucleases.
1. DNA break/repair assay in a human cell line.
[0066] LIG-34, LIG-34+, and LIG-34++ were evaluated for DNA cleavage activity in a reporter assay in a human cell-line as follows: a defective GFP reporter cassette was generated by first cloning a 5' 480 bp fragment of the GFP gene into Mzel/Hmdlll-digested pcDNA5/Fi?r(Invitrogen Corp., Carlsbad, CA, USA) resulting in the plasmid, pGF. Next, a 3' 480 fragment of the GFP gene (including a 240 bp sequence duplicated in the 5' 480 bp fragment) was cloned into 5αmHI/A7zoI-digested pGF. The resulting plasmid, pGFFP, consists of the 5' 2/3 rd of the GFP gene followed by the 3' 2/3 rd of the GFP gene, interrupted by 24 bp of the pcDNA5/FRT polylinker. To insert the LIG-34 recognition site into pGFFP, complimentary oligonucleotides encoding the binding site were annealed and ligated into HmdIII/i?αmHI-digested pGFFP, resulting in pGFFP.LIG34. This plasmid comprises, in 5' to 3' orientation: a CMV promoter, the 5' 2/3 of the GFP gene, a LIG-34 recognition site sequence, the 3' 2/3 of the GFP gene, and a BGH polyadenylation signal. In vivo cleavage of the LIG-34 site by the LIG-34 meganuclease is expected to stimulate homologous recombination between the two direct repeats of the GFP gene to yield a functional GFP gene (Figure 2). 293. GFFP. LIG34 cells were generated by stably integrating this reporter cassette into the genome of FIp-In 293 cells using the FIp-In system according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA).
[0067] The coding sequences of LIG-34, LIG-34+, and LIG-34++ were inserted into to the mammalian expression vector pCI (Promega) under the control of a constitutive (CMV) promoter. 293.GFFP.LIG34 cells at -90% confluence were transfected in 24-well plates with either 800 ng pCI GFP (to determine transfection efficiency), 800 ng empty pCI (no enzyme control) or 400 ng pCI encoding LIG-34, LIG-34+, or LIG-34++ balanced with 400 ng empty pCI, using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA). 96 hours post-trans fection, cells were washed in PBS, trypsinized, and resuspended in PBS supplemented with 3% FBS. Cells were assayed for GFP activity using a Cell Lab Quanta SC MPL flow cytometer and the accompanying Cell Lab Quanta Analysis software (Beckman Coulter).
[0068] It was found that 293.GFFP.LIG34 cells were GFP+ with frequencies of 2.5%,
5.3%, and 7.1%, respectively, when expressing LIG-34, LIG-34+, and LIG-34++ (Figure 3). Cells transfected with an empty pCI expression vector were <°.1% GFP+. These results indicate that the LIG-34 meganucleases are capable of cleaving the LIG-34 recognition site in vivo with the expected order of activities.

Claims

1. A rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 1.
2. A rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 12.
3. A rationally-designed meganuclease having the amino acid sequence of SEQ ID NO: 13.
4. A rationally-designed meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3.
5. A method for the production of a recombinant maize plant in which a sequence of interest is integrated the maize genome, the method comprising transforming a maize cell or embryo with: (a) a first DNA molecule comprising: a DNA sequence encoding a meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3; and a promoter suitable for the expression of such a meganuclease in maize; and (b) a second DNA molecule comprising a sequence of interest.
6. A method for the production of a recombinant maize plant in which a sequence of interest is integrated the maize genome, the method comprising transforming a maize cell or embryo with: (a) a first DNA molecule comprising: a DNA sequence encoding a meganuclease having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 12 and/or SEQ ID NO: 13 which recognizes and cleaves the double-stranded DNA sequence of SEQ ID NO: 2 and SEQ ID NO:3; and
- 25 - a promoter suitable for the expression of such a meganuclease in maize; and (b) a second DNA molecule comprising: a sequence of interest flanked on one side by a DNA sequence with homology to 50- 900 consecutive base pairs of SEQ ID NO: 10 and flanked on the other side by a DNA sequence with homology to 50-900 consecutive base pairs of SEQ ID NO: 11.
7. The method of claim 5 or 6 in which the sequence of interest is flanked on at least one side by the first nine nucleotides from the meganuclease recognition sequence of SEQ ID NO: 2 or SEQ ID NO: 3.
8. The method of claim 5 or 6 wherein the maize cell or embryo is transformed with a molecule comprising the first DNA molecule and the second DNA molecule.
9. The method of claim 5 or 6 wherein the maize cell or embryo is transformed with a molecule comprising the first DNA molecule and the second DNA molecule and wherein SEQ ID NO: 2 or SEQ ID NO: 3 is located between the DNA sequence encoding the meganuclease and the sequence of interest.
10. A maize plant with a chromosome comprising a composite sequence, the composite sequence comprising: a sequence of interest; a first sequence comprising 50-900 base pairs from SEQ ID NO: 10 immediately upstream of the sequence of interest; and a second sequence comprising 50-900 base pairs from SEQ ID NO: 11 immediately downstream of the sequence of interest.
11. The maize plant of claim 10 wherein the composite sequence is free of retroviral sequences, Agrobacterium tumefaciens sequences and/or transposon sequences.
12. The maize plant of claim 10 with a single composite sequence in said chromosome.
13. The maize plant of claim 10 wherein the 3' nucleotide of the first sequence corresponds to a nucleotide selected from the group consisting of nucleotides 950-961 of SEQ ID NO: 10.
14. The maize plant of claim 10 wherein the 5' nucleotide of the second sequence
- 26 - corresponds to a nucleotide selected from the group consisting of nucleotides 1-11 of SEQ ID NO: 11.
15. The maize plant of any one of claims 10-14 wherein the sequence of interest comprises an exogenous gene.
16. A maize plant having a sequence of interest inserted in its chromosome, wherein the sequence of interest is inserted into SEQ ID NO: 2 and SEQ ID NO: 3.
17. The maize plant of claim 16 wherein the sequence of interest is inserted only once into said chromosome.
18. The maize plant of claim 16 or 17 wherein the sequence of interest comprises an exogenous gene.
- 27 -
PCT/US2009/035719 2008-03-11 2009-03-02 Rationally-designed meganucleases for maize genome engineering WO2009114321A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/879,428 US8338157B2 (en) 2008-03-11 2010-09-10 Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3561308P 2008-03-11 2008-03-11
US61/035,613 2008-03-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/879,428 Continuation US8338157B2 (en) 2008-03-11 2010-09-10 Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering

Publications (3)

Publication Number Publication Date
WO2009114321A2 true WO2009114321A2 (en) 2009-09-17
WO2009114321A8 WO2009114321A8 (en) 2009-12-17
WO2009114321A3 WO2009114321A3 (en) 2010-02-04

Family

ID=41065759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/035719 WO2009114321A2 (en) 2008-03-11 2009-03-02 Rationally-designed meganucleases for maize genome engineering

Country Status (2)

Country Link
US (1) US8338157B2 (en)
WO (1) WO2009114321A2 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064736A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
WO2011064750A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
WO2011104382A1 (en) * 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
WO2011154159A1 (en) * 2010-06-09 2011-12-15 Bayer Bioscience N.V. Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
WO2011154158A1 (en) * 2010-06-09 2011-12-15 Bayer Bioscience N.V. Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
WO2012021797A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
DE112010004584T5 (en) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh Chimeric endonucleases and applications thereof
US8338157B2 (en) 2008-03-11 2012-12-25 Precision Biosciences, Inc. Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering
EP2568048A1 (en) * 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
WO2012129373A3 (en) * 2011-03-23 2013-03-14 Pioneer Hi-Bred International, Inc. Methods for producing a complex transgenic trait locus
WO2013050318A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013050611A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013050593A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013053686A1 (en) 2011-10-10 2013-04-18 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013053711A1 (en) 2011-10-10 2013-04-18 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013066805A1 (en) 2011-10-31 2013-05-10 Pioneer Hi-Bred International, Inc. Improving plant drought tolerance, nitrogen use efficiency and yield
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
WO2013109754A1 (en) 2012-01-17 2013-07-25 Pioneer Hi-Bred International, Inc. Plant transcription factors, promoters and uses thereof
WO2013136274A1 (en) 2012-03-13 2013-09-19 University Of Guelph Myb55 promoter and use thereof
WO2013138358A1 (en) 2012-03-13 2013-09-19 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
WO2013136273A2 (en) 2012-03-13 2013-09-19 University Of Guelph Methods of increasing tolerance to heat stress and amino acid content of plants
WO2013138399A1 (en) 2012-03-14 2013-09-19 E. I. Du Pont De Nemours And Company Improving agronomic characteristics of plants through abph2
WO2013138309A1 (en) 2012-03-13 2013-09-19 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
WO2013166113A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2013188501A1 (en) 2012-06-15 2013-12-19 Pioneer Hi-Bred International, Inc. Genetic loci associated with resistance of soybean to cyst nematode and methods of use
WO2013188291A2 (en) 2012-06-15 2013-12-19 E. I. Du Pont De Nemours And Company Methods and compositions involving als variants with native substrate preference
US20140179005A1 (en) * 2011-06-01 2014-06-26 Precision Biosciences, Inc. Methods and Products for Producing Engineered Mammalian Cell Lines With Amplified Transgenes
WO2014100525A2 (en) 2012-12-21 2014-06-26 Pioneer Hi-Bred International, Inc. Compositions and methods for auxin-analog conjugation
WO2014143996A2 (en) 2013-03-15 2014-09-18 Pioneer Hi-Bred International, Inc. Compositions and methods of use of acc oxidase polynucleotides and polypeptides
WO2014153234A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2014153242A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2014160122A1 (en) 2013-03-14 2014-10-02 Pioneer Hi-Bred International, Inc. Maize stress related transcription factor 18 and uses thereof
WO2014164828A2 (en) 2013-03-11 2014-10-09 Pioneer Hi-Bred International, Inc. Methods and compositions employing a sulfonylurea-dependent stabilization domain
WO2014164466A1 (en) 2013-03-12 2014-10-09 E. I. Du Pont De Nemours And Company Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
WO2014164775A1 (en) 2013-03-11 2014-10-09 Pioneer Hi-Bred International, Inc. Methods and compositions to improve the spread of chemical signals in plants
WO2015057600A1 (en) 2013-10-18 2015-04-23 E. I. Du Pont De Nemours And Company Glyphosate-n-acetyltransferase (glyat) sequences and methods of use
WO2016000647A1 (en) 2014-07-03 2016-01-07 Pioneer Overseas Corporation Plants having enhanced tolerance to insect pests and related constructs and methods involving insect tolerance genes
WO2016100333A1 (en) 2014-12-15 2016-06-23 Syngenta Participations Ag Pesticidal microrna carriers and use thereof
WO2017066597A1 (en) 2015-10-16 2017-04-20 Pioneer Hi-Bred International, Inc. Generating maize plants with enhanced resistance to northern leaf blight
WO2018078390A1 (en) 2016-10-31 2018-05-03 Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences Compositions and methods for enhancing abiotic stress tolerance
WO2018160485A1 (en) 2017-03-03 2018-09-07 Pioneer Hi-Bred International, Inc. Non-destructive assay for soybean seeds using near infrared analysis
WO2020005667A1 (en) 2018-06-29 2020-01-02 Pioneer Hi-Bred International, Inc. Compositions and methods for editing an endogenous nac gene in plants
WO2020081173A1 (en) 2018-10-16 2020-04-23 Pioneer Hi-Bred International, Inc. Genome edited fine mapping and causal gene identification
WO2021252238A1 (en) 2020-06-12 2021-12-16 Pioneer Hi-Bred International, Inc. Alteration of seed composition in plants
WO2021257206A1 (en) 2020-06-17 2021-12-23 Pioneer Hi-Bred International, Inc. Generating maize plants with enhanced resistance to northern leaf blight
US11560568B2 (en) 2014-09-12 2023-01-24 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
WO2023012342A1 (en) 2021-08-06 2023-02-09 Kws Vegetables B.V. Durable downy mildew resistance in spinach
WO2023102393A1 (en) 2021-11-30 2023-06-08 Pioneer Hi-Bred International, Inc. High efficiency large scale chromosomal genome manipulation
WO2023109887A1 (en) 2021-12-15 2023-06-22 南京金斯瑞生物科技有限公司 Method for detecting integration site
WO2024020360A1 (en) 2022-07-18 2024-01-25 Pairwise Plants Services, Inc. Mustard green plants named 'pwrg-1', 'pwrg-2,' and 'pwsgc'
WO2024023578A1 (en) 2022-07-28 2024-02-01 Institut Pasteur Hsc70-4 in host-induced and spray-induced gene silencing

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086995A1 (en) * 2011-06-21 2014-02-05 Pioneer Hi Bred Int METHODS AND COMPOSITIONS TO PRODUCE PLANTS WITH MALE STERILITY
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
JP6777549B2 (en) 2014-03-14 2020-10-28 サイバス ユーエス エルエルシー Methods and Compositions for Increasing the Efficiency of Target Gene Modification Using Oligonucleotide Mediated Gene Repair
KR20230053709A (en) 2014-09-07 2023-04-21 셀렉타 바이오사이언시즈, 인크. Methods and compositions for attenuating anti-viral transfer vector immune responses
BR112018016278A2 (en) 2016-02-09 2019-01-02 Cibus Europe Bv methods and compositions for increasing the efficiency of targeted gene modification using oligonucleotide mediated gene repair
JP2020529206A (en) 2017-07-31 2020-10-08 アール・ジエイ・レイノルズ・タバコ・カンパニー Methods and compositions for virus-based gene editing in plants
EP3679134A1 (en) 2017-09-08 2020-07-15 Keygene N.V. Balanced indels
EP3694543A1 (en) 2017-10-13 2020-08-19 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
CA3087266A1 (en) 2018-01-09 2019-07-18 Cibus Us Llc Shatterproof genes and mutations
IL276957B2 (en) 2018-02-26 2023-12-01 Antolrx Inc Tolerogenic liposomes and methods of use thereof
CN114206396A (en) 2019-05-28 2022-03-18 西莱克塔生物科技公司 Methods and compositions for attenuating an immune response against an antiviral transfer vector
WO2021173528A1 (en) 2020-02-28 2021-09-02 Pioneer Hi-Bred International, Inc. Sorghum doubled haploid production system
WO2022171783A1 (en) 2021-02-11 2022-08-18 Koninklijke Nederlandse Akademie Van Wetenschappen Curing disease by transcription regulatory gene editing
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2024023067A1 (en) 2022-07-25 2024-02-01 Koninklijke Nederlandse Akademie Van Wetenschappen Curing disease by transcription regulatory gene editing
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078552A1 (en) * 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317509A3 (en) 1987-11-16 1990-01-31 Ciba-Geigy Ag Targetted incorporation of genes into a plant genome
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
EP0602899B1 (en) 1992-12-09 2004-10-20 New England Biolabs, Inc. Modified proteins containing controllable intervening sequences and methods of their production
US5527695A (en) 1993-01-29 1996-06-18 Purdue Research Foundation Controlled modification of eukaryotic genomes
US6051409A (en) 1995-09-25 2000-04-18 Novartis Finance Corporation Method for achieving integration of exogenous DNA delivered by non-biological means to plant cells
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6265196B1 (en) 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US7135608B1 (en) 1997-08-28 2006-11-14 The Salk Institute For Biological Studies Site-specific recombination in eukaryotes and constructs useful therefor
US6114600A (en) 1997-10-31 2000-09-05 The United States Of America As Represented By The Secretary Of Agriculture Resolution of complex integration patterns to obtain single copy transgenes
AU3928899A (en) 1998-04-28 1999-11-16 Novartis Ag Site-directed transformation of plants
US6781032B1 (en) 1998-08-14 2004-08-24 The Regents Of The University Of California Homologous recombination in plants
WO2000046385A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting dna
WO2000046386A2 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6746870B1 (en) 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
AU6529900A (en) 1999-08-09 2001-03-05 Monsanto Technology Llc Novel cloning methods and vectors
AU7447000A (en) 1999-09-30 2001-04-30 Izumu Saito Dna containing variant frt sequences
US7126041B1 (en) 1999-12-10 2006-10-24 North Carolina State Unversity High efficiency gene targeting in plants
BR0112633A (en) 2000-07-21 2003-09-16 Us Agriculture Method for replacing, translocating and stacking DNA in eukaryotic genomes
DE10131786A1 (en) 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Recombination systems and methods for removing nucleic acid sequences from the genome of eukaryotic organisms
WO2003012036A2 (en) 2001-07-27 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
EP1427828B1 (en) 2001-09-14 2010-04-28 Cellectis Random integration of a polynucleotide after in vivo linearization
GB0126251D0 (en) 2001-11-01 2002-01-02 Imp College Innovations Ltd Methods
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20050238658A1 (en) 2002-03-05 2005-10-27 Maskell Duncan J Transposon
US20060130179A1 (en) 2002-03-29 2006-06-15 Suttie Janet L Lambda integrase mediated recombination in plants
FR2843404A1 (en) 2002-08-07 2004-02-13 Cellectis Testing cleavage activity of endonucleases, useful as reagents in molecular biology and genomic engineering, that generate overhangs, comprises testing their effects on duplex DNA substrates
CA2497913C (en) 2002-09-05 2014-06-03 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7285699B2 (en) 2002-10-07 2007-10-23 Stowers Institute For Medical Research Ends-out gene targeting method
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
JP2006518372A (en) 2003-01-28 2006-08-10 セレクティス Use of meganuclease and its application to induce homologous recombination ex vivo and into vivo in vertebrate body tissues
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ES2320228T3 (en) 2003-11-18 2009-05-20 Bayer Bioscience N.V. IMPROVED ADDRESSED DNA INSERT IN PLANTS.
US7935862B2 (en) 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
US20060288444A1 (en) 2004-08-13 2006-12-21 Mccarroll Robert Soybean polymorphisms and methods of genotyping
AU2005287547B2 (en) 2004-09-23 2010-09-02 Basf Plant Science Gmbh Recombination cassettes and methods for sequence excision in plants
WO2006074956A1 (en) 2005-01-14 2006-07-20 Bayer Bioscience N.V. Improved plant transformation methods
EP2327771A1 (en) 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007034262A1 (en) 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
DE602006017527D1 (en) 2005-04-04 2010-11-25 Bayer Bioscience Nv METHOD AND MEANS FOR REMOVAL OF A SELECTED DNA SEQUENCE
AP2693A (en) 2005-05-27 2013-07-16 Monsanto Technology Llc Soybean event MON89788 and methods for detection thereof
AU2006304668B2 (en) 2005-10-18 2013-03-07 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
PL2049663T3 (en) 2006-08-11 2015-08-31 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
US20080083042A1 (en) 2006-08-14 2008-04-03 David Butruille Maize polymorphisms and methods of genotyping
CA2664414C (en) 2006-09-28 2016-07-12 Bayer Bioscience N.V. Methods and means for removal of a selected dna sequence
WO2008093152A1 (en) 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
WO2008102199A1 (en) 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
CA2688246C (en) 2007-05-31 2018-06-19 Basf Plant Science Gmbh Method of excising a nucleic acid sequence from a plant genome
WO2008148559A1 (en) 2007-06-05 2008-12-11 Bayer Bioscience N.V. Methods and means for exact replacement of target dna in eukaryotic organisms
WO2008149176A1 (en) 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
AR067114A1 (en) 2007-06-22 2009-09-30 Monsanto Technology Llc METHODS AND COMPOSITIONS TO SELECT LOCI BASED ON PERFORMANCE AND EXCESSION OF CHARACTERISTICS
CA2691440A1 (en) * 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
WO2009114321A2 (en) 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078552A1 (en) * 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK May 2002 'Zea Mays LIGULELESS1 (Ig1) Gene, Complete Cds.' Database accession no. AF451895 *
KAPLINSKY ET AL.: 'Utility and Distribution of Conserved Noncoding Sequences in the Grasses.' PNAS vol. 99, no. 9, April 2002, pages 6147 - 6151 *

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2568048A1 (en) * 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
US8912392B2 (en) 2007-06-29 2014-12-16 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
US8338157B2 (en) 2008-03-11 2012-12-25 Precision Biosciences, Inc. Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering
WO2011064750A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
WO2011064736A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
US9404099B2 (en) 2009-11-27 2016-08-02 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
DE112010004583T5 (en) 2009-11-27 2012-10-18 Basf Plant Science Company Gmbh Chimeric endonucleases and applications thereof
DE112010004584T5 (en) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh Chimeric endonucleases and applications thereof
DE112010004582T5 (en) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh Optimized endonucleases and applications thereof
WO2011104382A1 (en) * 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
AU2011264074B2 (en) * 2010-06-09 2015-01-22 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
AU2011264075B2 (en) * 2010-06-09 2015-01-29 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
KR101995698B1 (en) 2010-06-09 2019-07-03 바이엘 크롭사이언스 엔.브이. Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
WO2011154159A1 (en) * 2010-06-09 2011-12-15 Bayer Bioscience N.V. Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
WO2011154158A1 (en) * 2010-06-09 2011-12-15 Bayer Bioscience N.V. Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
CN109504700A (en) * 2010-06-09 2019-03-22 拜尔作物科学公司 Plant Genome transformation in commonly on nucleotide sequence modified plant genome Method and kit for
JP2013531489A (en) * 2010-06-09 2013-08-08 バイエル・クロップサイエンス・エヌ・ヴェー Methods and means for modifying plant genomes in nucleotide sequences commonly used in plant genome engineering
KR20130083433A (en) * 2010-06-09 2013-07-22 바이엘 크롭사이언스 엔.브이. Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
CN103119169A (en) * 2010-06-09 2013-05-22 拜尔作物科学公司 Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
WO2012021797A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
WO2012021785A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity
WO2012129373A3 (en) * 2011-03-23 2013-03-14 Pioneer Hi-Bred International, Inc. Methods for producing a complex transgenic trait locus
CN103842511A (en) * 2011-03-23 2014-06-04 先锋国际良种公司 Methods for producing a complex transgenic trait locus
US10030245B2 (en) 2011-03-23 2018-07-24 E I Du Pont De Nemours And Company Methods for producing a complex transgenic trait locus
EP3489366A1 (en) * 2011-06-01 2019-05-29 Precision Biosciences, Inc. Methods for producing engineered mammalian cell lines with amplified transgenes
EP2714936A4 (en) * 2011-06-01 2015-07-29 Prec Biosciences Inc METHOD AND PRODUCTS FOR PRODUCING MANIPULATED MAMMALIC CELL LINES WITH REINFORCED TRANSGENES
US9822381B2 (en) 2011-06-01 2017-11-21 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
EP3683319A1 (en) * 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
US20140179005A1 (en) * 2011-06-01 2014-06-26 Precision Biosciences, Inc. Methods and Products for Producing Engineered Mammalian Cell Lines With Amplified Transgenes
WO2013050318A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013050611A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013050593A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013053686A1 (en) 2011-10-10 2013-04-18 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013053711A1 (en) 2011-10-10 2013-04-18 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013066805A1 (en) 2011-10-31 2013-05-10 Pioneer Hi-Bred International, Inc. Improving plant drought tolerance, nitrogen use efficiency and yield
WO2013102875A1 (en) 2012-01-06 2013-07-11 Basf Plant Science Company Gmbh In planta recombination
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
WO2013109754A1 (en) 2012-01-17 2013-07-25 Pioneer Hi-Bred International, Inc. Plant transcription factors, promoters and uses thereof
WO2013138358A1 (en) 2012-03-13 2013-09-19 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
WO2013136274A1 (en) 2012-03-13 2013-09-19 University Of Guelph Myb55 promoter and use thereof
WO2013138309A1 (en) 2012-03-13 2013-09-19 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
WO2013136273A2 (en) 2012-03-13 2013-09-19 University Of Guelph Methods of increasing tolerance to heat stress and amino acid content of plants
WO2013138399A1 (en) 2012-03-14 2013-09-19 E. I. Du Pont De Nemours And Company Improving agronomic characteristics of plants through abph2
WO2013166113A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
CN104411823A (en) * 2012-05-04 2015-03-11 纳幕尔杜邦公司 Compositions and methods comprising sequences having meganuclease activity
US10150956B2 (en) 2012-05-04 2018-12-11 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
US9499827B2 (en) 2012-05-04 2016-11-22 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
US9909110B2 (en) 2012-05-04 2018-03-06 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2013188501A1 (en) 2012-06-15 2013-12-19 Pioneer Hi-Bred International, Inc. Genetic loci associated with resistance of soybean to cyst nematode and methods of use
WO2013188291A2 (en) 2012-06-15 2013-12-19 E. I. Du Pont De Nemours And Company Methods and compositions involving als variants with native substrate preference
WO2014100525A2 (en) 2012-12-21 2014-06-26 Pioneer Hi-Bred International, Inc. Compositions and methods for auxin-analog conjugation
WO2014164775A1 (en) 2013-03-11 2014-10-09 Pioneer Hi-Bred International, Inc. Methods and compositions to improve the spread of chemical signals in plants
WO2014164828A2 (en) 2013-03-11 2014-10-09 Pioneer Hi-Bred International, Inc. Methods and compositions employing a sulfonylurea-dependent stabilization domain
WO2014164466A1 (en) 2013-03-12 2014-10-09 E. I. Du Pont De Nemours And Company Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
WO2014153242A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2014160122A1 (en) 2013-03-14 2014-10-02 Pioneer Hi-Bred International, Inc. Maize stress related transcription factor 18 and uses thereof
WO2014153234A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2014143996A2 (en) 2013-03-15 2014-09-18 Pioneer Hi-Bred International, Inc. Compositions and methods of use of acc oxidase polynucleotides and polypeptides
WO2015057600A1 (en) 2013-10-18 2015-04-23 E. I. Du Pont De Nemours And Company Glyphosate-n-acetyltransferase (glyat) sequences and methods of use
WO2016000647A1 (en) 2014-07-03 2016-01-07 Pioneer Overseas Corporation Plants having enhanced tolerance to insect pests and related constructs and methods involving insect tolerance genes
US12173294B2 (en) 2014-09-12 2024-12-24 Corteva Agriscience Llc Generation of site specific integration sites for complex trait loci in corn and soybean, and methods of use
US11560568B2 (en) 2014-09-12 2023-01-24 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
WO2016100333A1 (en) 2014-12-15 2016-06-23 Syngenta Participations Ag Pesticidal microrna carriers and use thereof
WO2017066597A1 (en) 2015-10-16 2017-04-20 Pioneer Hi-Bred International, Inc. Generating maize plants with enhanced resistance to northern leaf blight
WO2018078390A1 (en) 2016-10-31 2018-05-03 Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences Compositions and methods for enhancing abiotic stress tolerance
WO2018160485A1 (en) 2017-03-03 2018-09-07 Pioneer Hi-Bred International, Inc. Non-destructive assay for soybean seeds using near infrared analysis
WO2020005667A1 (en) 2018-06-29 2020-01-02 Pioneer Hi-Bred International, Inc. Compositions and methods for editing an endogenous nac gene in plants
WO2020081173A1 (en) 2018-10-16 2020-04-23 Pioneer Hi-Bred International, Inc. Genome edited fine mapping and causal gene identification
WO2021252238A1 (en) 2020-06-12 2021-12-16 Pioneer Hi-Bred International, Inc. Alteration of seed composition in plants
WO2021257206A1 (en) 2020-06-17 2021-12-23 Pioneer Hi-Bred International, Inc. Generating maize plants with enhanced resistance to northern leaf blight
WO2023012342A1 (en) 2021-08-06 2023-02-09 Kws Vegetables B.V. Durable downy mildew resistance in spinach
WO2023102393A1 (en) 2021-11-30 2023-06-08 Pioneer Hi-Bred International, Inc. High efficiency large scale chromosomal genome manipulation
WO2023109887A1 (en) 2021-12-15 2023-06-22 南京金斯瑞生物科技有限公司 Method for detecting integration site
WO2024020360A1 (en) 2022-07-18 2024-01-25 Pairwise Plants Services, Inc. Mustard green plants named 'pwrg-1', 'pwrg-2,' and 'pwsgc'
WO2024023578A1 (en) 2022-07-28 2024-02-01 Institut Pasteur Hsc70-4 in host-induced and spray-induced gene silencing

Also Published As

Publication number Publication date
WO2009114321A8 (en) 2009-12-17
US8338157B2 (en) 2012-12-25
WO2009114321A3 (en) 2010-02-04
US20110113509A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
US8338157B2 (en) Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering
US20240132862A1 (en) Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
Gao et al. Heritable targeted mutagenesis in maize using a designed endonuclease
JP6050861B2 (en) A rationally designed single-chain meganuclease with a non-palindromic recognition sequence
Antunes et al. Targeted DNA excision in Arabidopsis by a re-engineered homing endonuclease
US20130224863A1 (en) Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
CN101849010A (en) Methods for altering the genome of a monocot plant cell
US20130340121A1 (en) Temperature-Dependent Meganuclease Activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09719702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09719702

Country of ref document: EP

Kind code of ref document: A2